Genetic Characterization of Pediatric T-cell Acute Lymphoblastic Leukemia

Karrman, Kristina

2014

Link to publication

Citation for published version (APA):
Karrman, K. (2014). Genetic Characterization of Pediatric T-cell Acute Lymphoblastic Leukemia Division of Clinical Genetics, Lund University

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Genetic Characterization of Pediatric T-cell Acute Lymphoblastic Leukemia

Kristina Karrman

DOCTORAL DISSERTATION
by due permission of the Faculty of Medicine, Lund University, Sweden.
To be defended in Belfragesalen, BMC, Lund.
On Friday November 14, 2014, at 9:30 AM.

Faculty opponent
Professor Frank Speleman
The aim of my thesis has been to characterize genetically pediatric T-cell acute lymphoblastic leukemia (T-ALL). Articles I and II focus on molecular characterization of translocations involving T-cell receptor (TCR) loci. These types of aberration are characteristic for T-ALL and have previously proved pivotal in the identification of genes implicated in leukemogenesis. The translocation t(12;14)(p13;q11) was shown to result in overexpression of CCND2. The t(12;14) is the first neoplasia-associated translocation shown to result in overexpression of CCND2 and the first example of a targeted deregulation of a member of the cyclin-encoding gene family in T-ALL. Cyclin D proteins are crucial to the cell cycle machinery and hence potential oncogenes. The second translocation cloned, t(X;7)(q22;q34), had not previously been reported in a neoplastic disorder. Breakpoint analysis revealed IRS4 as a novel translocation partner to a TCR locus, resulting in deregulated IRS4 expression, both at the gene and protein level. IRS4 plays an important part in several intracellular signalling cascades, including PI3K-AKT, known to be activated in T-ALL. In a subsequent work, I showed that IRS4 can also be targeted by alternative mechanisms in T-ALL, apart from TCR translocations, namely by mutations (Article IV).

In Article III, clinical characteristics and cytogenetic aberrations were ascertained and reviewed in a large, population-based Nordic series of 285 pediatric T-ALLs. Survival analyses revealed a correlation between rare TCR translocations and inferior outcome, an association that awaits confirmation in a separate study.

Finally, I used several different techniques – fluorescence in situ hybridization, single nucleotide polymorphism (SNP) array, and deep sequencing of 75 selected candidate genes – to characterize co-operative genetic aberrations in a consecutive series of paediatric T-ALL (Article V). One common change identified by SNP array was segmental uniparental isodisomy (sUPID). This aberration was seen in 44% of the investigated cases, with most being sUPID9p that always were associated with homozygous CDKN2A deletions, with a heterozygous deletion occurring prior to the sUPID9p in all instances. Among the 75 genes investigated by deep sequencing, 14 were mutated in 28 cases. The genes targeted are involved in signalling transduction, epigenetic regulation, and transcription. In some cases, NOTCH1 mutations were seen in minor subclones and lost at relapse, showing that such mutations also can be secondary events. These findings support a multistep leukemogenic process in pediatric T-ALL.

In summary, through different approaches and by various methods, the articles included in this thesis have deciphered genetic aberrations in pediatric T-ALL, contributing to a better understanding of leukemogenesis.

Key words pediatric, T-cell, acute lymphoblastic leukemia, genetic characterization
Genetic Characterization of Pediatric T-cell Acute Lymphoblastic Leukemia

Kristina Karrman
# Contents

Preface ........................................... 7  
Articles included in the thesis .................. 9  
Abbreviations .................................... 11  
Biological background .......................... 13  
   The thymus .................................... 13  
   The T-cell ..................................... 13  
      T-cell differentiation ....................... 13  
      T-cell receptors ............................ 15  
      T-cell functions ............................ 17  

T-cell acute lymphoblastic leukemia (T-ALL) ........... 19  
   Early descriptions of leukemia ............... 19  

Characteristics of pediatric T-ALL .................. 20  
   Definitions .................................... 20  
   Epidemiology .................................. 21  
   Etiology ...................................... 21  
   Symptoms, findings, and patient characteristics 23  
   Diagnostic modalities ......................... 24  
   Treatment, MRD, and prognosis ................ 26  

Genetic aberrations in T-ALL ....................... 29  
   Historic landmarks in cancer genetics – at a glance 29  

Transformation from thymocyte to malignant T-cell .... 30  
   Chromosomal aberrations ..................... 31  
   Submicroscopic copy number alterations and uniparental isodisomy 38  
   Gene mutations ................................ 42  
   Genetic aberrations in pediatric T-ALL – take-home message 46  
   Epigenetic alterations .......................... 47  
   Gene expression ................................ 48  
   Tumor evolution ................................ 50  

Prognostic relevance of T-ALL-associated aberrations 51
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synopsis of the articles included in the thesis</td>
<td>53</td>
</tr>
<tr>
<td>Future Perspectives</td>
<td>55</td>
</tr>
<tr>
<td>Summary in Swedish</td>
<td>57</td>
</tr>
<tr>
<td>Acknowledgments</td>
<td>61</td>
</tr>
<tr>
<td>References</td>
<td>65</td>
</tr>
</tbody>
</table>
Preface

One hundred years ago, in 1914, Boveri’s article “Concerning the Origin of Malignant Tumors” was published, in which he proposed that tumors arise as a consequence of incorrect chromosome combinations. Boveri’s prescient ideas have since been confirmed, and the efforts of many subsequent scientists have resulted in major contributions to the cancer genetic landscape. However, the map still contains unexplored territories. Today, novel molecular methods give us unprecedented possibilities to investigate the genetic code and further explore and explain the field of cancer genetics.

Leukemia is the most common childhood malignancy, of which T-cell acute lymphoblastic leukemia (T-ALL) comprises a minor part. Genetic characterization has revealed several characteristic, leukemia-associated aberrations in T-ALL. Nevertheless, not all T-ALL cases can be classified by our current genetic knowledge. This implies that there are still unrecognized genetic changes important for T-cell oncogenesis. The aim of my thesis has been to characterize genetically pediatric T-ALL.

This thesis is divided into three sections. The first part provides a biological background to T-ALL, introducing the thymus and the T-cell. The second part is mainly focused on the clinical features, but will also address the epidemiological and etiological aspects of pediatric T-ALL. In the third and final part, I review the current cancer genetic landscape of T-ALL and I point out the fields to which my research work has contributed.

Lund, October 2014
This thesis is based on the following articles, which will be referred to in the text by their Roman numerals (Articles I-V):


### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALL</td>
<td>Acute lymphoblastic leukemia</td>
</tr>
<tr>
<td>BAC</td>
<td>Bacterial artificial chromosome</td>
</tr>
<tr>
<td>BCP</td>
<td>B-cell precursor</td>
</tr>
<tr>
<td>bHLH</td>
<td>Basic helix-loop-helix</td>
</tr>
<tr>
<td>BM</td>
<td>Bone marrow</td>
</tr>
<tr>
<td>C</td>
<td>Constant</td>
</tr>
<tr>
<td>CD</td>
<td>Cluster of differentiation</td>
</tr>
<tr>
<td>CIMP</td>
<td>CpG island methylator phenotype</td>
</tr>
<tr>
<td>CGH</td>
<td>Comparative genomic hybridization</td>
</tr>
<tr>
<td>CNAs</td>
<td>Copy number alterations</td>
</tr>
<tr>
<td>CNS</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>CpG</td>
<td>Cytosine-phosphate-guanine</td>
</tr>
<tr>
<td>D</td>
<td>Diversity</td>
</tr>
<tr>
<td>DN</td>
<td>Double negative</td>
</tr>
<tr>
<td>DNMTs</td>
<td>DNA methyltransferases</td>
</tr>
<tr>
<td>DP</td>
<td>Double positive</td>
</tr>
<tr>
<td>DSBs</td>
<td>Double strand breaks</td>
</tr>
<tr>
<td>ETP</td>
<td>Early T-cell precursor</td>
</tr>
<tr>
<td>ETPs</td>
<td>Early thymic progenitors</td>
</tr>
<tr>
<td>FISH</td>
<td>Fluorescence <em>in situ</em> hybridization</td>
</tr>
<tr>
<td>HD</td>
<td>Heterodimerization domain</td>
</tr>
<tr>
<td>HLA</td>
<td>Human leukocyte antigen</td>
</tr>
<tr>
<td>HR</td>
<td>High risk</td>
</tr>
<tr>
<td>iAMP21</td>
<td>Intrachromosomal amplification of chromosome 21</td>
</tr>
</tbody>
</table>
Ig  Immunoglobulin
IR  Intermediate risk
J   Joining
LMO LIM-domain-only
LOH Loss of heterozygosity
MHC Major histocompatibility complex
MRD Minimal residual disease
NGS Next-generation sequencing
NOPHO Nordic Society of Paediatric Haematology and Oncology
pEFS Probability of event-free survival
PEST Proline (P), glutamic acid (E), serine (S), and threonine (T) rich
pOS Probability of overall survival
PRC2 Polycomb repressive complex 2
RNA-seq RNA sequencing
RQ-PCR Real-time quantitative polymerase chain reaction
RT-PCR Reverse transcriptase polymerase chain reaction
SNP Single nucleotide polymorphism
SP Single positive
SR Standard risk
sUPID Segmental uniparental isodisomy
T-ALL T-cell acute lymphoblastic leukemia
TCR T-cell receptor
TdT Terminal deoxynucleotidyl transferases
T-LBL T-cell lymphoblastic lymphoma
UPID Uniparental isodisomy
V Variable
WBC White blood cell
wUPID Whole chromosome uniparental isodisomy
Biological background

The thymus

The thymus is an organ in the mediastinum, located right behind the sternum. During the early years of life, the thymus is prominent, but with increasing age a loss of tissue mass and structure takes place, a process called involution (Shanley et al., 2009). The ancient Greeks knew about this organ – the name is believed to derive either from the Greek word thumos, roughly meaning spirit, soul, and courage, or from the plant Thymus vulgaris, possibly due to a vague resemblance of the thymus to the leaf of the thyme (Lavini et al., 2008). However, the function of the thymus remained elusive for centuries. It was not until the 1960s that it was shown that the thymus plays a major role in lymphopoiesis and that it has important immunological functions (Miller, 1961). It is now well known that the thymus orchestrates the complex symphony of the T-cell differentiation that results in functional, self-tolerant T-cells (Miller, 2011).

The T-cell

T-cell differentiation

The thymus is dependent upon input of progenitor cells from the bone marrow (BM). The intrathymic differentiation process is depicted in Figure 1. Early thymic progenitors (ETPs) are the most immature thymocytes, retaining both B-cell and myeloid lineage potential; however, this potential is gradually lost as differentiation proceeds (Luc et al., 2012). The presence or absence of specific surface markers, termed cluster of differentiation (CD), characterizes the maturing cells. The earliest thymocytes are double negative (DN) with regard to the absence of both CD4 and CD8. The DN cells proliferate and migrate from the cortico-medullary junction and make a loop through the outer cortex during which the microenvironment is crucial for the maturation process. One major input to sustain T-cell development and early differentiation is the interaction between NOTCH1, a transmembrane receptor, and its cell bound ligands (Delta-like 1, 3, and 4; and Jagged 1 and 2).
Figure 1. The intrathymic pathway followed by T-cells during the maturation process. Early thymic progenitors (ETPs) enter the thymus through vessels in the corticomedullary junction. Through their thymic circuit, T-cells will undergo distinct developmental stages, depicted by expression of characteristic sets of surface markers and T-cell receptor (TCR) molecules. As immigrants move outward towards the cortex, the double negative (DN) cells will initiate TCR rearrangements. Expression of pre-TCR takes place in the outmost periphery of the cortex. T-cells that pass the so called β-selection will transform to double positive (DP) cells and subsequently express the final TCR αβ at the cell surface. Stringent criteria are applied to ensure sensitivity and specificity of the newly assembled TCRs. The T-cells are exposed to the individual’s unique major histocompatibility complex (MHC) proteins and only T-cells with TCRs that bind to self MHC with an appropriate affinity will survive, i.e., positive selection. Cells that pass this check point will transform to single positive (SP) cells and migrate to the thymic medulla. In this part of the thymus, there are cells that display self antigens. Negative selection eliminates cells that bind to a self antigen. Eventually, after a strenuous differentiation process eliminating 95% of the cells, mature T-cells are ready to leave the thymus and to start their immunological mission. Graphics adapted from Aifantis et al. (2008) and Rothenberg et al. (2008).

The T-cell receptor (TCR) genes are then rearranged in the DN cells in a strictly ordered manner, resulting in either αβ or γδ TCRs (see below). The majority of the cells express αβ TCRs, which are assembled in a stepwise fashion. First, the TCR β
protein is expressed and incorporated in a prototype receptor, *i.e.*, pre-TCR. Thymocytes with a functional pre-TCR pass the so called β-selection that enables them to differentiate further. Second, the TCR α protein is transcribed, after which mature αβ TCR complexes can be assembled and presented on the cell surface. While the cells express pre-TCR, upregulation of both CD4 and CD8 results in double positive (DP) cells. The αβ T-cells can only recognize antigens when they are presented by a cell bound to major histocompatibility complex (MHC) proteins. MHC proteins, called human leukocyte antigen (HLA) in humans, are able to present a very large number of peptides on the cell surface. The TCRs associate with CD3 in complexes optimal for MHC recognition, in conjunction with the coreceptors CD4 or CD8. MHC classes I and II are structurally very similar but are expressed differentially: class I is present on virtually all nucleated cells and associates with CD8, whereas class II is expressed mainly by macrophages, dendritic cells, and B-cells and is associated with CD4. Cortical thymic epithelial cells express the individual’s unique MHC proteins together with peptides. Only the DP cells with TCRs that bind to a peptide-MHC complex with an appropriate affinity will survive, a process called positive selection. Depending on if the TCR recognizes MHC class I or class II proteins, the T-cell either retains CD8 or CD4, respectively, and hence transforms to a single positive (SP) cell. The SP cells migrate towards the central medulla where they are exposed to epithelial cells expressing MHC-self-antigen complexes. Negative selection functions to destroy SP cells that bind with high affinity to self-antigens; this process reduces autoreactivity. In short, the development of ETPs into mature T-cells is an intricate process where complicated somatic rearrangements of the TCR genes have to be completed and the functionality and tolerance of the receptor scrutinized by positive and negative selection. Less than 5% of the thymocytes generated in the thymus leave as mature T-cells; this loss of more than 95% of cells is the price to pay for an effective, self-tolerant immune defence (Egerton *et al.*, 1990; Aifantis *et al.*, 2008; Rothenberg *et al.*, 2008; Miller, 2011).

**T-cell receptors**

The function of the adaptive immune system depends on the T-cells’ ability to produce an astonishing variety of antigen receptors – the TCRs (Tonegawa, 1983; Hedrick *et al.*, 1984) (Figure 2). There are four TCR genes: *TRA* (located at 14q11, α protein), *TRB* (7q34, β protein), *TRD* (14q11, δ protein), and *TRG* (7p14, γ protein); the *TRD* locus maps within the *TRA* locus. A functional TCR is a heterodimer consisting either of αβ or γδ chains, and each T-cell expresses approximately 30,000 identical TCRs on the cell surface. The TCR genes are composed of several variable (V), diversity (D; only present in *TRB* and *TRD*), joining (J), and constant (C) segments. Together, *TRA* and *TRB* contain around 190 functional gene segments, whereas *TRD* and *TRG* consists of considerably fewer segments (Nishana & Raghavan, 2012). During T-cell differentiation, V(D)J
Figure 2. T-cell receptor (TCR) structures are assembled from multiple separate gene segments. The TCR genes TRB, TRA, and TRD (nestled within TRA) consist of several different segments, denoted variable (V), diversity (D), joining (J), and constant (C). TRG is not graphically depicted but is organized as the other TCR genes. In the process of TRA recombination, TRD will be excised due to its intragenic position. The combinatorial possibilities created by V(D)J recombination are astonishing and are a cornerstone in our immune defence. The numbers of the different segments were ascertained from Atlas of Genetics and Cytogenetics in Oncology and Haematology (http://atlasgeneticsoncology.org/). Graphics adapted from Nemazee (2006).

recombination takes place, a process strictly regulated as to lineage and developmental stage. In addition, the recombination follows a hierarchical order with regard to the TCR genes and their segments. The recombination process results in the joining of a specific V to a J segment and, in TRB and TRD, to a D segment (Figure 2). The combinatorial possibilities of V(D)J joining are the backbone of the diversity of the TCRs. V(D)J recombination is dependent upon the recombination activating genes RAG1 and RAG2 that encode the RAG proteins. These proteins bind to specific
recombination signal sequences immediately adjacent to the different TCR segments and introduce double strand breaks (DSBs) of the DNA. The RAG proteins will then cooperate with non-homologous end joining proteins to join the DNA ends. In the process of joining the fragments, non-templated nucleotides may be introduced by terminal deoxynucleotidyl transferases (TdT) or lost, a process known as junctional diversification. This adds not only to the variability of the TCRs but also to the risk of the rearrangements being out-of-frame. There are two TRB alleles but the vast majority of T-cells will only express one functional β TCR chain; this monospecificity is ensured by allelic exclusion that functions through asynchronous recombination and negative feedback mechanisms. Asynchronous recombination is accomplished by affecting the recombination efficacy in multiple ways, including the localisation of gene loci to repressive nuclear compartments and chromatin conformations affecting the proximity of TCR gene segments. These mechanisms, in addition to the error prone VDJ process with a high built in failure rate, make it unlikely that both TRB alleles undergo functional rearrangements at the same time. Negative feedback mechanisms are initiated once an in-frame VDJ rearrangement is produced, manifested by the pre-TCR. The critical signalling pathways that regulate feedback inhibition are only partially understood; however, the pre-TCR takes part in the initiation. Decontraction and reduced chromatin accessibility will function to prevent further recombination at the other TRB allele (Schlissel, 2003; Skok et al., 2007; Schlimgen et al., 2008; Kondilis-Mangum et al., 2011; Schatz & Ji, 2011).

T-cell functions

B and T lymphocytes are derived from the same progenitor cell and are morphologically indistinguishable. They nevertheless have distinct, albeit interconnected, functions in the adaptive immune defence, i.e., antibody- and T-cell-mediated immune responses, respectively (Miller, 2002). Mature T-cells exit from the thymus and migrate via the blood to peripheral lymphoid tissues. A minority of T-cells displays γδ TCRs and these cells mainly function in epithelia, such as the skin and gut mucosa. Based on the expression of the surface receptors CD4 or CD8, two major subclasses of αβ T-cells have been identified: the helper and the cytotoxic T-cells, respectively. Cytotoxic, CD8-positive T-cells kill infected cells or tumor cells, while helper, CD4-positive T-cells aid in the activation of cells involved in the immune response, such as B-cells and cytotoxic T-cells (Cantor & Boyse, 1975). A minority of CD4-positive T-cells develops into regulatory T-cells in the thymus and they play an important role in immunological self-tolerance. Self-reactive T-cells that have escaped thymic elimination are suppressed in the periphery by regulatory T-cells (Hori et al., 2003). Mature, naïve T-cells have a lifespan of several years. The immune repertoire, i.e., the TCR diversity, is acquired in childhood after which the thymus involutes. The quantity of T-cells in adults mainly relies on peripheral T-cell division; however, some thymic activity is retained into adulthood (den Braber et al., 2012).
T-cell acute lymphoblastic leukemia (T-ALL)

Early descriptions of leukemia

“Several cases exist with a great excess of white blood cells (...) Blood of such patients contains so many white blood cells that at first glance I thought they contained purulent matter. In fact I believe the excess of white blood cells is due to an arrest of maturation of blood. From my theory on the origin of blood cells, the overabundance of white blood cells should be the result of an arrest of the development of intermediate cells.”

The French physician Alfred Donné wrote this in 1844 (Donné, 1844; Degos, 2001; Xavier, 2013). Donné was a pioneer in microscopy and when he examined the blood from patients with splenomegaly he noted that what had previously been thought of as “pus in the blood” was in fact leukocytosis, and he suggested that the excess of white blood cells (WBC) could be due to a maturation arrest, a fact now well recognized in leukemia. The first reports recognizing leukemia as a distinct clinical entity are, however, often attributed to John Hughes Bennett and Rudolf Virchow. In 1845, Bennett, a professor at the Institutes of Medicine in Edinburgh, performed an autopsy on a 28-year-old man with hepatosplenomegaly. An extensive post mortem report was published, in which Bennett stated that the aberrant blood finding was independent of inflammation, concluding that it represented a systemic blood disorder and called the disease leucocythemia (Bennett, 1845; Kampen, 2012). Just a few months later, Virchow, a 24-year-old German pathologist at the Charité Hospital in Berlin, reported similar findings in an autopsy on a 50-year-old woman with edema, splenomegaly, and nose bleeding. When examining the blood, he found a skewed balance between red and white blood cells in comparison with normal blood. His publication was entitled “Weisses Blut” and in a paper a few years later, Virchow named the disease “Leukämie” (Virchow, 1845, 1848). Thus, the early understanding of leukemia in the mid-nineteenth century was a gradual process, involving several physicians. The first reported case of childhood leukemia was provided by Henry William Fuller and concerned a 9-year-old girl who presented at the St George’s Hospital in London in 1850. The child had frequent hemorrhages, enlarged spleen, and leukocytosis, and died after a few months. Recent reviews of Fuller’s detailed
notes make it reasonably to believe, however, that the girl had an unusual form of childhood leukemia, namely chronic myeloid leukemia (Fuller, 1850; Piller, 2001). The distinctions between acute and chronic leukemia as well as between leukemias originating from myeloid or lymphoid lineages were made in reports by Nikolaus Friedrich and Paul Ehrlich, respectively (Friedrich, 1857; Ehrlich, 1879). In the late 1860s, the BM was recognized as the site for hematopoiesis and a few years later, leukemic cells were also shown to derive from the BM (Neumann, 1872). The relatively high prevalence of acute leukemia in children was first recognized in 1917 through an epidemiological survey on 1457 cases of leukemia collected by Gordon Ward while on war service with the Royal Army Medical Corps (Ward, 1917). More than 50 years later, in 1973, an article was published on a case of pediatric acute leukemia where the lymphoblasts displayed T-cell surface markers, and in a paper a few years later, T-ALL was established as a clinically as well as biologically distinct disease entity (Borella & Sen, 1973; Sen & Borella, 1975). Thus, T-ALL is a surprisingly late addition to the acute leukemia group.

Characteristics of pediatric T-ALL

Definitions

Acute lymphoblastic leukemia (ALL) comprises three major subclasses: B-cell precursor (BCP) ALL, mature B-cell (Burkitt) leukemia, and T-ALL. When referring to childhood ALL in general, one usually means BCP ALL because that entity comprises approximately 85% of all pediatric ALL cases (Swerdlow et al., 2008). Pediatric T-cell malignancies include T-ALL and T-cell lymphoblastic lymphoma (T-LBL), both included as T lymphoblastic leukemia/lymphoma in the current World Health Organization classification (Swerdlow et al., 2008). T-ALL and T-LBL are usually considered to be different manifestations of the same disease, with the extent of BM involvement being the main feature to distinguish T-ALL (>25% BM blasts) from T-LBL (minimal BM involvement) (Swerdlow et al., 2008). However, even though the entities display overlapping clinical, morphologic, and immunophenotypic features, some studies have identified distinct gene expression profiles, indicating a possibly greater biological difference than previously believed (Burkhardt, 2010; Basso et al., 2011). T-ALL is a malignancy originating from an immature thymocyte in the thymus. The malignant clone will proliferate and spread throughout the body, preferentially in the bone marrow, peripheral blood, lymph nodes, and central nervous system (CNS).
Epidemiology

Leukemia is the most common childhood malignancy, accounting for one-third of all pediatric cancers in developed countries (Steliarova-Foucher et al., 2004). ALL constitutes approximately 80% of all cases of childhood leukemia.

Patient characteristics are distinctly different between BCP ALL and T-ALL. BCP ALL has a marked incidence peak between 2 to 6 years of age, and the sex ratio shows only a slight male predominance with a male/female ratio of 1.2. In contrast, T-ALL has a flatter incidence curve (the median age at diagnosis is 9 years) and there is a marked male predominance – three times as many boys as girls are diagnosed with T-ALL (Forestier & Schmiegelow, 2006; Article III).

The incidence of pediatric ALL in Sweden is one of the highest in the world, with ~4 cases per 100 000 children per year (aged 0-14 years). In absolute numbers this translates into approximately 70 children and adolescents being diagnosed with ALL each year in Sweden. T-ALL comprises 10-15% of childhood ALL; the annual incidence is 0.36 cases per 100 000/year (Hjalgrim et al., 2003). Some studies have reported an increased rate of ALL over time (Steliarova-Foucher et al., 2004); however, the number of pediatric cases diagnosed in Sweden during the last decades has been quite constant (Hjalgrim et al., 2003). Geography, mirroring ethnicity and socioeconomic status, influences the frequency of ALL; the lowest ALL incidences are reported in the sub-Saharan African countries (Stiller & Parkin, 1996). Differences in recorded number of childhood ALL cases, with regard to time trends and geographic origins, may be due to a number of factors, some of which more attributable to administrative factors and health service availability and quality (Adamson et al., 2005). This notwithstanding, if reliable incidence differences were to be observed, that could provide important clues as to etiological factors (Hrušák et al., 2002; Lim et al., 2014).

Etiology

Why is ALL a common childhood malignancy? Etiological studies have mainly addressed risk factors for the more common form of ALL, namely BCP ALL. Pediatric T-ALL is a rare disease which makes it difficult to obtain robust results in etiological studies. However, investigations of causative mechanisms for BCP ALL may, at least to some extent, be relevant also to T-ALL, given that both diseases originate from hematopoietic progenitor cells.

Prenatally and during early life, lymphopoiesis is very active, with progenitor cells proliferating at a high rate and somatic rearrangements creating the immune repertoire. The intense kinetics makes the cells vulnerable to environmental insults that could result in leukemia-associated genetic aberrations. In the majority of childhood ALL cases, including T-ALL, leukemogenesis requires several genetic
events in a single cell, as illustrated by: i) mouse models; ii) the long latency between the first initiating event and overt leukemia in children; and iii) the presence of leukemia-associated anomalies in healthy individuals (Larson et al., 1996; Greaves & Wiemels, 2003; Yasuda et al., 2014). This is in line with, at minimum, a two-step model for cancer development (Knudson, 1971). In BCP ALL, the initiating event often occurs prenatally. This has been suggested also for some T-ALLs, although the origin of most T-ALL cases seems to be postnatal (Ford et al., 1997; Gale et al., 1997; Fischer et al., 2007; Eguchi-Ishimae et al., 2008). A genetic hallmark of T-ALL is TCR translocations (see section “Genetic aberrations in T-ALL” below). Conversely, IGH translocations are relatively rare in BCP ALL. However, the age profile for BCP ALL with IGH translocations matches the one for T-ALL, i.e., older children and adolescents (Russell et al., 2014). Thus, it seems that aberrations involving illegitimate rearrangements of immunoglobulin (Ig)/TCR loci could arise postnatally and might share a common etiological factor.

The only confirmed external causative mechanism for ALL is ionizing radiation, but because this is now a well-known risk factor, pre- and postnatal exposure is held to a minimum and irradiation should hence not contribute significantly to cases occurring today. Several other causative agents have been proposed, such as parental smoking, paint and household chemicals, pesticides, maternal diet, traffic fumes, and electric fields, but so far none has been shown to add convincingly to the incidence of childhood ALL (Eden, 2010; Wiemels, 2012).

That infections and/or the body’s response to them may promote leukemia development has been put forward in two separate, albeit somewhat overlapping, theories: “population mixing” and “delayed-infection” (Kinlen, 1988; Greaves, 1988). Kinlen’s hypothesis of population mixing postulates that leukemia may be the rare result of a common infection in a non-immune individual, a phenomenon most evident when there is an influx of new residents to a previously isolated community. However, in contrast to leukemia in animals and certain human malignancies, such as Burkitt lymphoma and adult T-cell leukemia, there is little evidence for direct viral transformation in childhood ALL (Eden, 2010). Greaves’ theory of delayed-infection postulates that a delayed exposure to common infections may trigger an aberrant immune response, thus creating an immunological milieu favoring leukemic development; however, the exact underlying mechanism is unclear (Greaves, 2006). Some circumstantial support for the “delayed-infection” theory comes from investigations showing that children who are exposed to common infections at an early age, measured as day-care attendance, have a reduced risk of ALL (Urayama et al., 2010).

Apart from external factors, could there be an inherent difference between children as to how susceptible they are to develop ALL? A few syndromes due to germline mutations in high-penetrance genes confer an increased risk of ALL, such as ataxia-telangiectasia that is associated with childhood lymphoid malignancies, in particular T-ALL (Seif, 2011). However, hereditary syndromes are a rare cause of ALL. This
notwithstanding, a study of late T-ALL relapses revealed that the leukemia- and clone-specific markers were completely different between diagnosis and recurrence in eight out of the 22 (36%) investigated cases, suggestive of new primary T-ALLs rather than relapses. One explanation could be that patients with two suspectedly separate T-ALLs are predisposed to ALL development; indeed, one of the patients in that study had a constitutional genetic aberration, del(11)(p12p13), previously associated with T-ALL (Szczepański et al., 2011). However, the existence of a pre-leukemic, ancestral clone could potentially give rise to two seemingly different leukemias (Shlush et al., 2014).

Furthermore, genome-wide association studies have identified five common polymorphisms at 7p12.2 (IKZF1), 9p21.3 (CDKN2A), 10p12.2-12.31 (BMI1-PIP4K2A), 10q21.2 (ARID5B), and 14q11.2 (CEBPε) that influence the risk, albeit with low impact, of childhood ALL. The polymorphism in CDKN2A is significantly associated also with T-ALL (Papaemmanuil et al., 2009; Sherborne et al., 2010; Xu et al., 2013). If genetic and/or environmental risk factors play a role in the etiology of ALL, one would expect that siblings of children with ALL have an increased risk of this disease. In fact, in a recent study, a high ALL-subtype concordance rate was shown within sibships affected by multiple cases of pediatric ALL. Notably, in five of the six sibships presented, where the first case was T-ALL, the subsequent case (or cases) was also T-ALL. This indicates that etiologic factors, and a possibly increased sibling risk, may be subtype-dependent (Schmiegelow et al., 2012). In conclusion, there is not a single cause of childhood ALL. This is not surprising considering how biologically and genetically diverse the disease is. Most likely, a combination of constitutional polymorphisms and different exposures will influence the ALL risk, potentially in a subtype-specific manner.

**Symptoms, findings, and patient characteristics**

The characteristic symptoms and findings in patients with ALL are caused by the BM failure due to maturation arrest. The lymphoblasts expand and hence normal hematopoiesis is repressed, resulting in a deficiency of normal blood cells. Fever, recurrent infections, fatigue, paleness, and skin/mucosal bleeding are frequent. Bone pain and arthralgia are also common. In a review of 189 childhood ALL patients, 96% had at least one classic leukemia symptom/finding; however, 4% were diagnosed accidentally (Bernbeck et al., 2009). Mediastinal mass and CNS involvement is particularly common in T-ALL, seen in approximately 60% and 10% of the patients, respectively, and may lead to dyspnea, headache, nausea, and visual impairment. The term “acute” in acute leukemia implies a rather short medical history, between days and weeks; however, in a proportion of patients (-10%), a duration of months has been noted (Bernbeck et al., 2009).
**Diagnostic modalities**

**Clinical evaluation**

The clinical evaluation assesses the patient’s general condition, including signs of the above-mentioned symptoms and findings. Neurological examination and palpation of the lymph nodes, abdomen, and testes are performed in order to identify lymphadenopathy, hepatosplenomegaly, and testicular and/or CNS involvement. Echocardiography, chest X-ray, and analysis of spinal fluid samples are also part of the diagnostic work-up.

**Blood samples**

Laboratory findings at diagnosis often include anemia, thrombocytopenia, and neutropenia. Although the term leukemia means “white blood”, implying leukocytosis, the WBC counts may be low, normal, or high. However, T-ALL patients most often display a high WBC count (median 66 x 10^9/l) and almost 50% have hyperleukocytosis >100 x 10^9/l. The differential blood count reveals the presence of peripheral lymphoblasts in most instances (Bernbeck et al., 2009; Article III).

**BM samples**

The BM aspirates are used for morphologic, cytochemical, immunophenotypic, and genetic analyses, with the latter comprising Ig/TCR monoclonality assays and cytogenetic/molecular genetic screening for acquired chromosomal changes. A BM infiltration of more than 25% lymphoblasts is a prerequisite for the diagnosis of ALL – T-ALL cases most often display a much higher percentage of BM infiltration. Because T-ALL and BCP ALL lymphoblasts are morphologically indistinguishable, cytochemical and immunophenotypic analyses are required to identify the lineage involved (Swerdlow et al., 2008).

**Immunophenotype**

As mentioned above, immunophenotyping is mandatory in order to distinguish between BCP ALL and T-ALL. CD3, expressed in the cytoplasm or on the cell surface, is T-lineage specific. In addition, TdT is usually positive as is a variable expression of CD1a, CD2, CD4, CD5, CD7, and CD8. Aberrant expression of one or both of the myeloid-associated markers CD13 and CD33 is seen in 20-30% of T-ALL cases.

As normal thymocytes mature, they are characterized by a changing pattern of CD markers, and T-ALL lymphoblasts will, to some extent, mirror the normal maturation process. The constellation of expressed CD markers in lymphoblasts can hence suggest the stage of the leukemic differentiation block. Four maturation subgroups of T-ALL have been defined according to the CD patterns: 1) pro-T: cCD3+/CD7+/CD2-/CD1a-/CD34+/-; 2) pre-T: cCD3+/CD7+/CD2+/CD1a-
/CD34+/--; 3) cortical T: cCD3+/CD7+/CD2+/CD1a+/CD34--; and 4) medullary T: cCD3+/CD7+/CD2+/CD1a-/CD34-/membrane CD3+. The immature pro- and pre-T stages are DN for CD4 and CD8 and the cortical T group is DP for CD4 and CD8, whereas the more mature medullary T-cell is SP for CD4 or CD8 (Bene et al., 1995; Swerdlow et al., 2008). A novel subtype of T-ALL – the early T-cell precursor ALL (ETP ALL) – is thought to originate from the earliest thymic immigrants (however, the cell of origin is debated; see section “Initiating event” below). ETP ALL displays a unique constellation of cell surface markers: CD1a-/CD8-/CD5(+) and expression of one or more myeloid- or stem cell-associated markers. Initially, ETP ALL was associated with a very dismal outcome; however, more recent studies allocate this subtype to intermediate risk (Coustan-Smith et al., 2009; Patrick et al., 2014).

TCR rearrangements

The TCR genes in normal T-cells are rearranged in a specific order during the differentiation process, starting with TRD followed by TRG, TRB, and TRA. Recombination of TRA will lead to the deletion of TRD since this gene is located within TRA. Each T-cell harbors a unique TCR rearrangement, like a DNA fingerprint, due to combinatorial and junctional diversification during the V(D)J recombination process (Figure 2). T-ALL is a clonal disease, i.e., all leukemic cells descend from a single ancestor. Thus, if the TCR genes are rearranged in the ancestor cell, identical rearrangements will be present in all the lymphoblasts. Hence, in contrast to an inflammatory process that gives rise to a polyclonal, diverse T-cell response, the malignant T-cells display TCR monoclonality. More than 90% of T-ALL cases display at least one monoclonal rearrangement, most often involving TRG and TRB. In a small subset of cases, biallelic TRG deletions are absent; this represents an immature form of T-ALL associated with a poor outcome (Gutierrez et al., 2010a). Cross-lineage immunoglobulin (Ig) rearrangements are found in 10-20% of T-ALL, whereas TCR rearrangements are found in up to 70% of BCP ALL. Thus, neither Ig nor TCR rearrangements are lineage-specific. They are hence not useful for lineage assignment. It should be emphasized that although TCR and Ig monoclonality is a marker for leukemic proliferation and useful for diagnostic purposes as well as for assessing the maturation stage of the leukemic clone and measuring minimal residual disease (MRD) (see below), they do not participate in the pathogenesis of T-ALL (Szczepeński et al., 2000; Brüggemann et al., 2004; Kraszewska et al., 2012a).

Genetic analyses of acquired chromosome changes

At the time of diagnosis, BM and blood samples are sent for cytogenetic and molecular genetic investigations. In the Nordic countries, mandatory genetic analyses are, at present, specified by the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-2008 protocol. The genetic investigations comprise chromosome banding analysis as a screening method and targeted analyses for the
translocations/fusion genes t(1;19)(q23;p13) [TCF3/PBX1], t(9;22)(q34;q11) [BCR/ABL1], and t(12;21)(p13;q22) [ETV6/RUNX1] using fluorescence in situ hybridization (FISH) or reverse transcriptase polymerase chain reaction (RT-PCR), intrachromosomal amplification of chromosome 21 (iAMP21) and dic(9;20)(p13;q11) using FISH, and 11q23/MLL rearrangements using FISH or Southern blot analyses (Toft et al., 2013). These targeted analyses are mainly directed towards BCP ALL-associated aberrations that are either rarely or never seen in T-ALL (Mansur et al., 2010).

In T-ALL, approximately 50-60% of the cases are cytogenetically abnormal, a frequency slightly lower than for pediatric ALL (60%) as a group (Heerema et al., 1998; Forestier et al., 2000; Schneider et al., 2000; Articles III and V). Characteristic T-ALL-associated chromosome changes are described in section: “Genetic aberrations in T-ALL” below. In contrast to BCP ALL, in which the genetic changes are diagnostically as well as prognostically important, the acquired genetic changes in T-ALL, although occasionally of diagnostic importance, play no role in the risk stratification and treatment intensity of T-ALL in the NOPHO ALL-2008 protocol.

**Treatment, MRD, and prognosis**

Assessment of biological and clinical features associated with inferior outcome is essential in order to ensure that the patients are treated according to the aggressiveness of the individual leukemia. Stratifying patients according to risk ensures that the most intense, and hence most toxic, treatments are limited to the group of patients with the highest risk of relapse, thus sparing standard risk cases undue toxicities. Adjusted treatment can abolish the adverse impact of many high risk features once associated with poor prognosis. The understanding of different risk groups and the practice of combinatorial chemotherapy has gradually evolved since the 1970s, something that has played a major role for the improved outcome for children with ALL.

The NOPHO ALL-2008 protocol comprises three different treatment groups: standard risk (SR), intermediate risk (IR), and high risk (HR). The stratification is based on B or T-cell immunophenotype, WBC count (<100 or ≥100 x 10⁹/l), CNS involvement, MRD status (days 15, 29, and 79), and the following specific genetic/chromosomal aberrations: hypodiploidy (<45 chromosomes or DNA index <0.85), t(1;19), dic(9;20), t(9;22), 11q23/MLL rearrangement, and iAMP21. Patients with t(9;22) are treated according to a separate protocol. In accordance to these criteria, T-ALL cases can be stratified either as IR or HR, never as SR (Toft et al., 2013).

The treatment is divided into three different phases: i) induction phase, aiming at remission within approximately 4 weeks; ii) consolidation/delayed intensification phase, to eradicate residual leukemic blasts and strengthen remission; and iii) maintenance phase, to stabilize further remission (Stanulla & Schrappe, 2009). The
treatment duration in NOPHO ALL-2008 is 2.5 years and the therapy is based on a combination of cytotoxic drugs, mainly targeting cellular mechanisms crucial for rapidly dividing cells, such as DNA replication. The drugs are administrated in different ways, including intrathecally to eradicate lymphoblasts in the CNS (in the NOPHO ALL-2008 protocol, CNS irradiation is no longer used). Allogeneic stem cell transplantation is an option for persistent ALL, based on MRD findings (Toft et al., 2013).

Monitoring MRD is of great importance in order to evaluate the effect of the given treatment as well as to assess the risk of relapse. MRD can be measured by three different approaches: 1) Real-time quantitative PCR (RQ-PCR) for monoclonal Ig/TCR rearrangements (see above); 2) flow cytometric detection of aberrant leukemic immunophenotypes (see above); and 3) RQ-PCR for fusion genes. The latter approach is seldom used in T-ALL because only a minority of such cases displays a suitable fusion target. The methodological sensitivities are $10^{-3} – 10^{-4}$, i.e., one leukemic cell among 1000-10,000 normal cells can be detected (Teachey & Hunger, 2013). In the NOPHO ALL-2008 protocol, MRD analysis is requested at days 15, 29, and 79. In T-ALL, MRD is measured by RQ-PCR for the Ig/TCR genes (Toft et al., 2013). Since antigen receptor genes might undergo continuous recombination during leukemic development, leading to Ig/TCR clonal evolution, it is advisable to monitor two rearrangements (Campana, 2010). It has been convincingly shown that MRD is a strong prognostic indicator – for T-ALL, MRD $\geq 10^{-3}$ at day 79 seems to constitute the most powerful predictor for relapse (Schrappe et al., 2011).

The survival of children diagnosed with ALL has improved dramatically since the 1960s, when only 5% of the patients were cured. In the previous NOPHO protocol (ALL-2000), the probabilities of 5-year event-free survival (pEFS) and overall survival (pOS) for BCP ALL exceeded 80% and 90%, respectively, while for T-ALL, the outcome was generally poorer with pEFS and pOS just over 60% and 70%, respectively (Schmiegelow et al., 2010). Relapsed pediatric T-ALL has a very dismal survival rate of only approximately 20%. Stagnation in the cure rate has been noted during the last 15 years. With increasing knowledge about the profiles of genetic aberrations in different ALL subtypes, the ultimate goal is to design treatments that target specific genetic mutations (Roti & Stegmaier, 2014).
Genetic aberrations in T-ALL

Historic landmarks in cancer genetics – at a glance

In the early 1900s, Theodor Boveri recognized chromosomes as the carriers of the Mendelian hereditary factors (Boveri, 1904). By observing dispermic sea urchin eggs he noted that the distribution of unequal number of chromosomes to daughter cells gave rise to specific characteristics due to the random combination of chromosomes inherited. Some sea urchin eggs with aberrant chromosomal compositions displayed abnormal growth, a trait shared with many tumors. In 1914, Boveri published “Concerning the Origin of Malignant Tumors” in which he proposed that tumors arise as a consequence of incorrect chromosome combinations. He also postulated several other cancer biology concepts, such as cell cycle checkpoints, oncogenes (“stimulatory chromosomes”), tumor suppressor genes (“inhibitory chromosomes”), inherited cancer predisposition, a multistep genetic process of malignant transformation, and a clonal origin of tumors (Boveri, 1914; Balmian, 2001; Harris, 2008). However, at that time, it was not technically feasible to prove (or disprove) Boveri’s hypotheses. Improvements in chromosome analyses between the mid 1950s and the early 1970s made it possible to identify and characterize the first cancer-associated aberrant chromosome, the Philadelphia chromosome, clearly supporting the view that chromosome abnormalities are important for carcinogenesis (Tjio & Levan, 1956; Nowell & Hungerford, 1960; Caspersson et al., 1970; Rowley, 1973). Furthermore, in the 1970s, the cellular origin of proto-oncogenes was described, showing that genes in normal cells can become deregulated and contribute to malignant development as oncogenes (Stehelin et al., 1976), and ten years later the same mechanism was described for tumor suppressor genes (Friend et al., 1986). Alfred Knudson demonstrated with the two-hit hypothesis that multiple mutations are necessary for the development of pediatric retinoblastoma (Knudson, 1971). So, many of Boveri’s prescient ideas have, by the work and efforts of many subsequent scientists, been proved to be correct.
Transformation from thymocyte to malignant T-cell

T-ALL is the consequence of a normal thymocyte transforming into its malignant counterpart. Although we know that this malevolent makeover is the result of accumulated intracellular genetic aberrations, many questions remain to be fully answered: Which genes are targeted? What mechanisms are used to alter gene expression? How many genetic changes are needed to complete the transformation? What is the duration between the first genetic hit and the clinical presentation of T-ALL? Can genetic aberrations in childhood T-ALL be utilized for more effective treatment?

During the last decade, our knowledge about genetic abnormalities in T-ALL has increased dramatically. As outlined below, studies of T-ALL have implicated numerous genes, targeted by various biological mechanisms, as drivers of leukemogenesis. However, the cellular effect of these seemingly diverse aberrations in multiple genes may well condense to a limited set of signaling pathways, controlling a few crucial biological features, i.e., cell fate, cell survival, and genome maintenance (Vogelstein et al., 2013). The number of genetic aberrations required for malignancy still remains to be fully elucidated. Recently, it has been demonstrated that a pediatric T-ALLs harbors a mean of approximately ten protein-affecting mutations (Zhang et al., 2012; De Keersmaecker et al., 2013; Tzoneva et al., 2013). For a single cell to acquire these crucial aberrations may, however, take several years. The duration between initiation and clinical presentation of pediatric T-ALL can be illustrated by the seemingly rare cases initiated prenatally or after gene therapy: the time span to overt T-ALL in these cases ranges from 1.3 to 11 years (Ford et al., 1997; Hacein-Bey-Abina et al., 2003; Eguchi-Ishimae et al., 2008; Braun et al., 2014). However, the median age for T-ALL in the three reported cases initiated prenatailly was 9 years, whereas the median time between gene therapy and disease was 3 years. This discrepancy could possibly be explained by the extensive insertional mutagenesis resulting from gene therapy, which might accelerate the leukemic transformation and hence not fully correspond to the normal duration between initiation and disease. Among the genetic aberrations characterized in T-ALL, a few therapeutic targets have been identified, such as NOTCH1, cell cycle regulators including cyclin D, and proteins involved in PI3K-AKT-mTOR pathway. This may in the future result in a more effective T-ALL treatment strategy (Roti & Stegmaier, 2014).

In this thesis I review the genetics of T-ALL, a map which has been drawn by the effort of many scientists. While journeying through the cancer genetic landscape I will point out the fields to which my research work has contributed. I will also briefly mention some of the techniques used in order to reach the various destinations.
Chromosomal aberrations

Cytogenetic studies

Chromosome banding analyses have long been the gold standard in cancer genetic research and many important leukemia-associated chromosomal rearrangements have been characterized by this technique since Rowley (1973) described the t(9;22)(q34;q11) in chronic myeloid leukemia. Cells need to be cultured in order to obtain condensed chromosomes for analysis; the number of metaphases is enriched by adding a mitotic inhibitor to the cell culture. Slides are prepared and the chromosomes stained, in most instances by Giemsa resulting in a G-banding pattern. The strength of chromosome banding analyses is the global overview over all chromosomes, allowing detection of numerical as well as structural changes. However, the technique has a relatively low resolution (~5 Mb) and is labor-intensive (Smeets, 2004).

As mentioned above, G-banding analyses reveal chromosomal abnormalities in 50-60% of pediatric T-ALL cases. Most abnormal karyotypes are pseudodiploid, with structural aberrations being more common than numerical changes. The most frequent cytogenetic aberrations are, in order of decreasing frequency, translocations involving the TCR loci, del(9p), +8, del(6q), and 11q23 rearrangements (Heerema et al., 1998; Schneider et al., 2000; Articles III and V).

TCR translocations

Translocations involving the TCR loci are the oncogenic hallmark of T-ALL. Structural aberrations affecting 14q11 [TRA/D] or 7q34 [TRB] are detected in approximately 20-30% of pediatric T-ALL cases by G-banding and/or FISH analyses (Cauwelier et al., 2006; Le Noir et al., 2012; Articles III and V).

Why are translocations targeting the TCR genes frequent in T-ALL? Factors triggering structural aberrations include DNA DSBs, spatial proximity between translocation partners, and inappropriate DNA repair. The somatic process of creating a vast TCR repertoire is dependent on the induction of multiple DSBs, facilitated by the RAG proteins. If there are foreign DNA DSBs present close by during the process of somatic TCR rearrangements, the repair system may misalign the strands. The repair system involved, non-homologous end joining, links DSBs without extensive sequence homology, hence facilitating illegitimate joining and chromosomal rearrangements (Bunting & Nussenzweig, 2013). It has been postulated that DSBs introduced in non-TCR loci are the result of RAG proteins recognizing cryptic recombination signal sequences elsewhere in the DNA. However, recent studies characterizing the breakpoints outside TCR have revealed that they are not, in the majority of cases, induced by RAG proteins (Le Noir et al., 2012; Larmonie et al., 2013). Alternative mechanisms facilitating DSBs include specific DNA features, such as cytosine-phosphate-guanine (CpG) dinucleotides (see section
“Epigenetic alterations” below) and repetitive elements, transcriptional activity, and cellular stress (Mani & Chinnaiyan, 2010). The majority of TCR translocations generated will probably not afford any advantages to the cell and will hence not be selected for. However, if DSBs occur in the vicinity of a proto-oncogene, a translocation may place the target gene under the control of TCR enhancers or promoters, resulting in a deregulated expression of the oncogene. Rarely, a TCR translocation can also function to silence a tumor suppressor gene (Le Noir et al., 2012). Consequently, translocations involving TCR loci may potentially be the spark that initiates tumor development (McCormack et al., 2010). So, to answer the question above, translocations involving TCR loci are common in T-ALL because the mechanistic requirements are met and the product has an oncogenic potential, conferring a selective edge.

TRD and TRB are the TCR loci most often illegitimately recombined; TRA is only rarely targeted and aberrations affecting TRG are virtually non-existent (Cauwelier et al., 2006; Le Noir et al., 2012). To date, 19 genes have been reported as partners in TCR translocations in T-ALL (Mitelman et al., 2014). The gene categories mainly targeted are class II basic helix-loop-helix (bHLH) and homeobox genes, encoding transcription factor proteins, and LIM-domain-only (LMO) genes, which modulate transcriptional complexes by protein-protein interactions. Other gene categories are more rarely implicated (Table 1). Specific genes, representing these categories, such as TAL1, HOXA, TLX1, TLX3, and LMO1/2, have been proposed to delineate separate molecular-cytogenetic T-ALL subgroups, characterized by distinct gene expression patterns (Van Vlierberghe et al., 2008a; Graux et al., 2006).

It has been shown that many TCR translocations are not detected by chromosome banding analyses (Cauwelier et al., 2006; Le Noir et al., 2012). There are several possible reasons for this: i) telomeric breakpoints (TRB; 7q34) resulting in submicroscopic alterations; ii) the translocations/inversions may be masked in more complex rearrangements; and iii) outgrowth of only normal cells in culture, resulting in a false normal karyotype. To overcome these shortcomings, TCR rearrangements can be identified using FISH, which is not dependent on metaphase spreads and that has a relatively high resolution (~100 kb). FISH is based on the hybridization of DNA probes to complementary target sequences. The probes are directly or indirectly labelled with a fluorochrome and can hence be detected in a fluorescence microscope. Depending on the probe design and the hybridization patterns, various chromosomal aberrations, such as numerical, structural, and copy number alterations, can be detected and characterized by FISH. However, the technique is limited to answer the question asked by the specific probe design. Hence, FISH analysis is mainly hypothesis-driven in contrary to chromosome banding analysis in which all chromosomes are screened (Bishop, 2010).
Table 1. Characteristic TCR rearrangements in pediatric T-ALL (Van Vlierberghe & Ferrando, 2012; Mitelman et al., 2014)

<table>
<thead>
<tr>
<th>Gene category/ function</th>
<th>Partner gene</th>
<th>Abnormality</th>
<th>Oncogenic function</th>
<th>Normal thymic expression/ differentiation block</th>
<th>Frequency*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class II bHLH/ transcription factor</td>
<td>TAL1</td>
<td>t(1;7)(p33;q34) t(1;14)(p33;q11)</td>
<td>Inhibits class I bHLH protein (E2A)</td>
<td>Very early stages/ late cortical, CD8+/CD4+</td>
<td>3-6%</td>
</tr>
<tr>
<td>LMO/ protein-protein interactions</td>
<td>LMO1</td>
<td>t(7;11)(q34;p15) t(11;14)(p15;q11)</td>
<td>Interacts with TAL1 to inhibit E2A. Self-renewal capacity‡</td>
<td>LMO2 very early stages, LMO1 not expressed/ late cortical, CD8+/CD4+</td>
<td>1%</td>
</tr>
<tr>
<td>Class I homebox/ transcription factor</td>
<td>HOXA cluster</td>
<td>inv(7)(p15q34) t(7;7)(p15;q34)</td>
<td>Impair T-cell differentiation</td>
<td>Some HOXA at early stages/ mature, CD2-/CD4+/CD8-</td>
<td>3-6%</td>
</tr>
<tr>
<td>Class II homebox/ transcription factor</td>
<td>TLX1</td>
<td>t(7;10)(q34;q24) t(10;14)(q24;q11)</td>
<td>Induction of aneuploidy§</td>
<td>No/ early cortical CD1a+/CD4+ /CD8-</td>
<td>5-10%</td>
</tr>
<tr>
<td>NOTCH receptor family/ transcription complex</td>
<td>NOTCH1</td>
<td>t(7;9)(q34;q34) t(9;14)(q34;q11)</td>
<td>T-cell determination, self-renewal, differentiation</td>
<td>Yes/ not applicable</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>D-type cyclin/ cell cycle</td>
<td>CCND2</td>
<td>t(7;12)(q34;p13) t(12;14)(p13;q11)</td>
<td>Proliferation</td>
<td>Yes/ not applicable</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Insulin receptor substrate family/ signal transduction</td>
<td>IRS4</td>
<td>t(X;7)(q22;q34)</td>
<td>Proliferation, cellular growth, survival</td>
<td>No/ not applicable</td>
<td>&lt;1%</td>
</tr>
</tbody>
</table>

*The frequency with which the gene is targeted by TCR rearrangements. The gene may well be deregulated in a much higher percentage of T-ALLs by other mechanisms, such as TAL1 and LMO2 by interstitial deletions, TLX3 by translocation to BCL11B instead of TCR genes, HOXA by chimeric oncogenes, e.g., SET/NUP214, PICALM/MLLT10, and MLL/MLLT1, and NOTCH1 by activating mutations.

‡Refers to the oncogenic potential of LMO2 (McCormack et al., 2010)

§Refers to the suggested oncogenic potential of TLX1 (De Keersmaecker et al., 2010).
In one study reporting a high incidence of submicroscopic TCR translocations in T-ALL, it was also noted that in some cases the translocation partner to TCR remained unidentified (Cauwelier et al., 2006). Although most of the translocations that remain to be cloned are likely to be individually rare, the partner gene may play a greater role in leukemogenesis than suggested based on incidence alone. A very pertinent example of this is NOTCH1, a gene which is involved in TCR translocations in only a handful of T-ALL cases (Ellisen et al., 1991; Mitelman et al., 2014) (Table 1). However, it is now known that a majority of T-ALLs harbors activating mutations in NOTCH1 (Weng et al., 2004). Hence, investigating seemingly quite rare TCR abnormalities in T-ALL may well provide insights into pathogenetically important cellular pathways. As part of my thesis work, two rare TCR translocations in T-ALL were molecular characterized (Articles I and II), namely t(12;14)(p13;q11) and t(X;7)(q22;q34), as detailed below.

Cytogenetic analyses of two pediatric T-ALL cases identified a translocation between the short arm of chromosome 12 and the long arm of chromosome 14; t(12;14)(p13;q11). FISH analyses revealed breakpoints in the TRA/D locus (14q11) and close to the cyclin D2 (CCND2) gene at 12p13. Gene expression analyses were performed by cDNA microarray and RQ-PCR. The two samples harboring t(12;14) displayed a marked overexpression of CCND2 compared with pediatric T-ALL cases without t(12;14). In conclusion, the recurrent t(12;14)(p13;q11) results in overexpression of CCND2 by juxtaposition of TRA/D regulatory elements to the vicinity of CCND2 (Clappier et al., 2006; Article I) (Figure 3). Prior to the cloning of the t(12;14), the D-cyclins, comprising CCND1, CCND2, and CCND3, had been implicated in T-cell malignancies. Knock-down of CCND3 inhibits proliferation of human T-ALL cells and cells infected with the HTLV-1 retrovirus, which is associated with adult T-cell leukemia/lymphoma, overexpress CCND1 and CCND2 (Mori et al., 2002; Sicinska et al., 2003). The t(12;14) was, however, the first neoplasia-associated translocation shown to result in overexpression of CCND2 and the first example of a targeted deregulation of a member of the cyclin-encoding gene family in a T-cell neoplasm. Subsequently, a t(6;14)(p21;q32) was shown to deregulate CCND3 by juxtaposition with the IGH locus in T-ALL (Nguyen-Khac et al., 2010). The cyclin D family is an essential part of the cell-cycle machinery (Figure 3). D-cyclins interact with the cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). This complex phosphorylates various substrates, such as the retinoblastoma 1 (RB1) protein, and promotes subsequent transition through the cell cycle. Aberrant cell cycle control is a common feature in human cancer. CCND1 is the most well-established oncogene within the cyclin D family, with deregulated expression by copy number changes, translocations, and mutations having been reported in a variety of cancers, including B-cell neoplasms (Musgrove et al., 2011).
Figure 3. Characterization of t(12;14)(p13;q11) resulting in overexpression of the cyclin D2 (CCND2) gene in pediatric T-ALL.

Ideogram for chromosomes 12 and 14 (depicted as at the UCSC Genome Browser: http://genome-euro.ucsc.edu/). The chromosomal breakpoints (bp) identified by FISH analyses are indicated by arrows. Arrows next to the genes indicate their transcriptional direction. The colored bars behind the ideograms highlight the translocated segments. Only one of the two derivate (der) chromosomes resulting from the translocation is shown, namely der(12)t(12;14)(p13;q11). CCND2 is retained on the der(12) and deregulated by TRA/D regulatory elements. Aberrant expression of CCND2 will affect the cell cycle machinery. The cell cycle is divided into four successive phases: S phase (DNA synthesis) in which the DNA is replicated; M phase (mitosis), in which the cell divides; and the two gap phases G1 and G2, which are periods of cell growth and mitosis preparations, respectively, including diverse control mechanisms to ensure that the cell is ready for division. The transition from one phase of the cell cycle to the next is controlled by cyclin-dependant kinases (CDKs) in complex with cyclin proteins. The INK4 family, including CDKN2A and CDKN2B, inhibits the mitogenic effect of CDK4 and CDK6. The CDK4/6-cyclin D complex phosphorylates the RB1 protein, resulting in subsequent release of the transcription factor E2F. Transcription of several genes, including cyclins A and E, is mediated by E2F. Cell cycle graphics adapted from Strauss et al. (2012).
As shown by us and others, D-cyclins are involved also in T-ALL and hence inhibition of their activity may compromise T-ALL progression. Indeed, therapeutic targeting of cyclin D3:CDK4/6 in T-ALL has yielded some promising results (Sawai et al., 2012).

The second TCR translocation in pediatric T-ALL characterized as part of my thesis work was t(X;7)(q22;q34). To map the breakpoints in Xq22 and 7q34 several FISH probes were used. The FISH analyses revealed a breakpoint at the TRB locus (7q34) and mapped the corresponding breakpoint to Xq22.3 (Figure 4). Gene expression analysis by RQ-PCR in the t(X;7)-positive case revealed a marked overexpression of the gene located closest to the Xq22.3 breakpoint, namely the insulin receptor substrate 4 (IRS4) gene. By Western blot analysis we could also show that IRS4 was expressed at the protein level. In addition, several cooperative genetic aberrations were identified: del(6q), STIL/TAL1 fusion, and a NOTCH1 mutation, in accordance with the fact that multiple genetic hits are required for T-ALL to occur (Kraszewska et al., 2012b). In conclusion, molecular genetic characterization of the t(X;7), a translocation not previously reported in a neoplastic disorder, revealed IRS4 as a novel translocation partner to a TCR locus (Article II) (Figure 4). IRS4 has subsequently been shown to be a recurrent target of TCR translocations in T-ALL. (Kang et al., 2012). The IRS family comprises four members (IRS1-4) that play a central role in maintaining basic cellular functions, e.g., growth and metabolism. The IRS proteins act as cytoplasmic mediators between multiple growth factor receptors that possess tyrosine kinase activity, such as the insulin and insulin-like growth factor-1 receptors. When phosphorylated, the IRS proteins, which do not contain any intrinsic enzymatic activity, will act as docking sites for several intracellular effector molecules and result in activation of multiple signalling pathways, including the PI3K-AKT and RAS/ERK (Mardilovich et al., 2009) (Figure 4). In humans, IRS1 and IRS2 are the most frequently expressed members, while IRS4, initially detected in human embryonic kidney cells, has only been detected in muscle and liver tissue (Lavan et al., 1997; Schreyer et al., 2003; Cuevas et al., 2007). Mice lacking Irs4 exhibit mild defects in growth, reproduction, and glucose homeostasis; mice without Irs1 or Irs2 display the same phenotype but with more pronounced features (Fantin et al., 2000). Although relatively little is known about the tumorigenic potential of IRS4, expression of this gene has been demonstrated in a human hepatoblastoma cell line and Irs4 has been implicated in proliferation of a murine T-cell lymphoma cell line (Ursø et al., 2003; Cuevas et al., 2007). Cancer cell lines with high IRS4 levels can drive signalling via the PI3K pathway, even in the absence of growth factors, and knockdown of IRS4 inhibits cell proliferation (Hoxhaj et al., 2013). IRS4 mutations have been detected in melanoma and both IRS2 and IRS4 mutations have been demonstrated in T-ALL (Kalender Atak et al., 2012; Shull et al., 2012; Article IV). Hence, by characterizing a rare TCR translocation, a potentially new oncogene in T-ALL was identified.
Figure 4. T-ALL-associated TCR translocation targeting IRS4, with a possible impact on the PI3K-AKT signaling pathway.

Ideogram for chromosomes X and 7 (depicted as at the UCSC Genome Browser: http://genome-euro.ucsc.edu/). FISH analyses were used to map the chromosomal breakpoints (bp), indicated by arrows. The positions of the TRB and IRS4 genes are specified and arrows show their transcriptional direction. Colored bars behind the ideograms highlight the translocated segments. Only the der(X)t(X;7)(q22;q34) is depicted, on which the created proximity of IRS4 and TRB is outlined. Aberrant expression of IRS4 may potentially affect several intracellular signaling pathways. However, the PI3K-AKT pathway has been delineated as one of the more important in leukemogenesis and is hence graphically outlined. Stimulation of receptor tyrosine kinases (RTK) by a growth hormone (GH) results in recruitment and phosphorylation of IRS4. Activated IRS4 will function as a docking site for phosphatidylinositol 3-kinase (PI3K). PI3K will subsequently convert phosphatidylinositol (4,5) biphosphate (PIP2) into phosphatidylinositol (3,4,5) triphosphate (PIP3). The phosphatase and tensin homolog (PTEN) dephosphorylates PIP3 and thereby terminates PI3K signaling. Deregulation, mainly through mutations, of PTEN is common in T-ALL. PIP3 recruits phosphatidylinositol-dependent kinase (PDK), which helps to activate the v-akt murine thymoma viral oncogene homolog (AKT). AKT mediates the activation and inhibition of several targets, resulting in proliferation, cellular growth, and survival (Engelman, 2009).
Submicroscopic copy number alterations and uniparental isodisomy

Array CGH analysis

Array-based technologies can detect copy number alterations (CNAs) at a higher resolution than conventional chromosome banding/FISH analyses and without the requirement for dividing cells. Two main types of platform are available: comparative genomic hybridization (CGH) and single nucleotide polymorphism (SNP) arrays (discussed below). Array CGH techniques have in the past used two different types of probe set: bacterial artificial chromosomes (BAC) or oligonucleotides. The method relies on competitive hybridization of differentially labeled tumor and normal samples to the probes on the array. Differences in hybridization signals will convey information regarding CNAs. The minimal size of an aberration that can be detected by the platform is referred to as resolution and is dependent on probe size and distribution as well as on array density. Oligonucleotides are short fragments with high coverage; thus, array CGH based on oligonucleotides has a superior resolution compared with BAC arrays (Maciejewski & Mufti, 2008; Maciejewski et al., 2009).

SNP array analysis

SNPs are common interindividuval DNA variations. By definition, a SNP is a single nucleotide substitution, leading to allele differences with the least common allele having a prevalence of 1% or more. There are over 63 million SNPs reported in the human genome (http://www.ncbi.nlm.nih.gov/SNP/; build 141). The effect of a SNP ranges from no phenotypic impact at all to disease-predisposing or even disease-causing, depending on its localization and effect on protein translation. Information about SNPs can be used in several research areas, such as genome-wide association studies, population genetics, and large-scale genome analysis. SNP array analysis has been utilized in research for almost a decade, providing valuable information on, e.g., genetic aberrations in leukemias (Mullighan et al., 2007).

The main advantage of SNP array compared with array CGH is the former method’s ability to detect copy number neutral loss of heterozygosity (LOH) in addition to CNAs. The SNP array technique is based on hybridization of fragmented genomic DNA to probes on an array. According to the Illumina platform, used in my thesis work, each probe targets a specific SNP in the genome, binding to the complementary DNA sequence and stopping one base before the SNP. Allele specificity can be conferred by single base extension using fluorescently labeled nucleotides. The specific signal emitted by the extended nucleotide when laser excited is recorded and the signal intensity is normalized against the average signal intensity and converted to a log2 ratio, which acts as a proxy for copy number. The signal also conveys data regarding genotype, denoting the SNP as hetero- or homozygous. Genotype information facilitates the interpretation of CNAs and, maybe more importantly, add data regarding copy number neutral LOH. When large regions contain only homozygous SNPs with no concurrent copy number alteration they may...
represent uniparental isodisomy (UPID), and if only encompassing part of a chromosome, it is denoted a segmental UPID (sUPID) (Maciejewski & Mufti, 2008; Maciejewski et al., 2009) (Figure 5). The sensitivity of the method refers to the minimal proportion of cells allowed to be detected, i.e., the method’s ability to detect minor clones, constituting either tumor heterogeneity or normal/tumor admixture. In Article V, an Illumina SNP array (HumanOmni1-Quad BeadChip) containing >1 million markers with a median marker spacing of 1.5 kb was used, generating a sensitivity of approximately 10-20% and a resolution of approximately 20 kb. To distinguish between constitutional variants and cancer-associated aberrations it is important to compare diagnostic and matched normal DNA samples and to use databases containing reported genomic variants (Heinrichs et al., 2010). Because of the great advantages of SNP arrays, despite their inability to detect balanced translocations, they are currently implemented in many centers for routine genetic analysis of pediatric leukemias (Wikhager et al., 2012).

Submicroscopic CNAs

Pediatric T-ALLs display a mean of 3-7 CNAs/case when investigated by SNP arrays. The vast majority of the CNAs (>75%) are deletions (Mullighan et al., 2008; Yu et al., 2011; Article V) and it has been suggested that RAG-mediated deletions contribute to the acquisition of some of these aberrations (Raschke et al., 2005; Mendes et al., 2014). The main oncogenic impact afforded by deletions is inactivation of tumor suppressor genes. In T-ALL, the chromosomal segment most commonly affected by deletions is 9p21 (Figure 5), encompassing the CDKN2A and CDKN2B genes at 9p21.3. Deletions of CDKN2A are seen in >70% of pediatric cases, with a concurrent CDKN2B deletion in a slightly lower frequency (Mullighan et al., 2008; Article V). CDKN2A encodes two separate proteins, CDKN2A and P14ARF, regulating the cell cycle through inactivation of CDK4/6 and stabilization of the TP53 protein, respectively. CDKN2B also codes for a CDK4/6 inhibitory protein, CDKN2B. Several other tumor suppressor genes have been shown to be deleted in T-ALL, although to a lesser extent, such as BCL11B (14q32.2), LEF1 (4q25), NF1 (17q11.2), PTPN2 (18p11.21), and WT1 (11p13) (Balgobind et al., 2008; Tosello et al., 2009; Gutierrez et al., 2010b; Kleppe et al., 2010; Gutierrez et al., 2011; Article V). Recently, recurrent deletions have been shown to target genes involved in epigenetic regulation, including EZH2 (7q36.1), PHF6 (Xq26.2), and SUZ12 (17q11.2) (Van Vlierberghe et al., 2010; Ntziachristos et al., 2012; Article V). Many of the above-mentioned tumor suppressor genes, with the possible exception of CDKN2A/2B, have also been shown to be targeted by inactivating mutations (Sulong et al., 2009; Van Vlierberghe & Ferrando, 2012).
Figure 5. Graphical output for chromosome segment 9p13-pter from a SNP array analysis of a T-ALL case. Each dot represents one marker, in most instances a SNP. The top panel depicts genotype information presented as a B allele frequency (BAF), calculated as the signal intensity for allele B/(signal intensities for alleles A and B). If the SNP is heterozygous, AB, the BAF is 0.5 (indicated by the red line), while if it is homo- or hemizygous, BB/B- or AA/A-, it will be either 1 or 0, respectively. The BAF allows for the detection of copy number neutral aberrations, such as segmental UPIDs (sUPIDs). The lower panel presents signal intensity data (R), calculated as the log2 ratio (log R ratio), that can be used to ascertain copy number alterations. If the SNP is present in two copies (normal diploid copy number), the log R ratio is 0 (indicated by the red line). Increased and decreased log R ratios correspond to gained and deleted regions, respectively. The T-ALL case in this figure displays an aberrant BAF for the chromosomal segment 9p21.1-pter. This area does not contain any heterozygous SNPs, i.e., no SNPs have a BAF value of 0.5 between 9p21.1 and pter. This BAF pattern could be the result of either an sUPID or a heterozygous deletion. To distinguish between these two aberration types information from the log R ratio is necessary. An sUPID does not affect the log R ratio, while a heterozygous deletion would result in a decreased ratio. The main part between 9p21.1 and pter does not demonstrate an alteration in the log R ratio; hence, the aberration affecting this segment is an sUPID (indicated by the blue bar). However, it is obvious that a second aberration affects band 9p21.3. The BAF pattern indicates that there are no SNPs to genotype, and the log R ratio is decreased. Thus, a homozygous deletion (indicated by the pink bar) is present within the sUPID. It should be noted that both the CDKN2A and CDKN2B genes will be deleted as a consequence of this aberration. In fact, sUPID for 9p with concurrent homozygous deletion of 9p21.3 is a recurrent mechanism for silencing CDKN2A and CDKN2B in T-ALL (Article V).
However, although tumor suppressor genes might be the most obvious targets for deletions, it has been shown that oncogenes can be activated by chromosomal losses through several different mechanisms. \( TAL1 \) (1p33) is often deregulated in T-ALL, occasionally as the result of a translocation between \( TAL1 \) and \( TRA/D \) or \( TRB \) (Table 1). However, in 10 to 40% of the cases, an interstitial 1p33 deletion places \( TAL1 \) under the control of the promoter of the neighboring gene \( STIL \), which is highly expressed in T-cells (Janssen et al., 1993; Yu et al., 2011; Article V). This promoter swapping results in overexpression of \( TAL1 \) (Ferrando et al., 2002). The oncogene \( LMO2 \) (11p13) is often deregulated in T-ALL through illegitimate TCR translocations (Table 1). Array analyses have revealed an alternative way of \( LMO2 \) activation, namely deletions encompassing a negative regulatory element in 11p12-p13, resulting in elevated \( LMO2 \) expression (Van Vlierberghe et al., 2006). Finally, submicroscopic deletions of 9q34 have been shown to result in the fusion gene \( SET/NUP214 \), which encodes a novel transcription factor that upregulates the \( HOXA \) genes (Van Vlierberghe et al., 2008b).

In spite of the fact that the vast majority of CNAs detected by arrays are deletions a few recurrent chromosomal gains have been identified in T-ALL. A fusion between \( NUP214 \) and \( ABL1 \) at 9q34 is amplified on episomes in ~5% of T-ALL cases (Graux et al., 2004). \( NUP214/ABL1 \) codes for a constitutively active tyrosine kinase. Although the clinical experience is limited, a few, but definitely not all, T-ALL patients with this fusion treated with tyrosine kinase inhibitors have responded well (Clarke et al., 2011). Another oncogene deregulated through gene duplication is \( MYB \) (6q23.3), which has also been shown to be targeted by TCR translocations (Clappier et al., 2007; Lahortiga et al., 2007).

**Uniparental isodisomy**

Copy number neutral stretches of LOH can arise through different mechanisms: i) as runs of homozygosity by descent, ii) meiotic UPID, and iii) mitotic UPID. A UPID is generated when both alleles are from the same parental origin and identical, hence giving rise to homozygosity (Engel, 1980). Homozygosity by descent is common in all populations and an increase in frequency and length is noted when there is close kinship between the parents (Kirin et al., 2010). Although homozygosity by descent is a normal finding it may represent a risk for recessive diseases. Meiotic missegregation may result in uniparental heterodisomy (meiosis I error) or isodisomy (meiosis II error) that can give rise to different syndromes, sometimes associated with an increased risk of cancer (Lapunzina & Monk, 2011). Most cancer-related studies have, however, focused on somatically acquired, mitotic UPIDs. The notion that mitotic UPIDs can be involved in cancer development was first described in 1983 and, with the advent of the SNP array technology, ample data supporting this association have been forthcoming (Cavenee et al., 1983; Fitzgibbon et al., 2005). The mechanisms for mitotic UPID are not fully elucidated; whole chromosome UPIDs (wUPIDs) can occur due to mitotic missegregation or may reflect the
underlying mechanism by which certain subtypes, such as high hyperdiploid ALL, originate, whereas sUPIDs may result from mitotic homologous recombination (Fitzgibbon et al., 2005; Paulsson & Johansson, 2009; Makishima & Maciejewski, 2011). Comparison between tumor and matched normal DNA is the most reliable method to distinguish between inherited runs of homozygosity and acquired mitotic UPIDs; however, size and localization may also be used for this discriminative purpose (Makishima & Maciejewski, 2011). The biological consequence of a sUPID is often duplication of a mutation/deletion in a tumor suppressor gene, resulting in homozygous silencing of the gene (Fitzgibbon et al., 2005). However, sUPIDs could also potentiate activating mutations in oncogenes or result in changes in epigenetic patterns. In pediatric ALL, mitotic UPIDs are detected in approximately 25% of cases (Kawamata et al., 2008); wUPIDs have been shown to be prevalent in high hyperdiploid ALL, with a frequency of close to 30% (Paulsson et al., 2010), and in near-haploid/low hypodiploid ALL (Safavi et al., 2013), whereas sUPIDs are seen in approximately 15% of pediatric ALL cases, with the most frequent gene segment targeted being 9p (Kawamata et al., 2008). There is some discrepancy with regard to how often deletions of \textit{CDKN2A} coincide with sUPID9p (Sulong et al., 2009). In our T-ALL series, sUPIDs were seen in 44% of the cases, with the vast majority affecting 9p. We could show that all cases with sUPID9p had a concurrent \textit{CDKN2A} deletion and because all homozygous \textit{CDKN2A} deletions associated with sUPID9p had identical breakpoints this strongly suggests that a heterozygous deletion occurred prior to the sUPID (Article V). Hence, in T-ALL, homozygous \textit{CDKN2A} deletions are frequently the result of a heterozygous \textit{CDKN2A} deletion with a subsequent mitotic recombination resulting in an sUPID9p (Figure 5).

**Gene mutations**

**Sanger sequencing**

G-banding, FISH, and SNP array analyses, as described above, detect numerical and structural aberrations as well as small deletions, duplications, and UPIDs, with a resolution down to less than 100 kb. However, to detect aberrations affecting only a few nucleotides, such as base pair substitutions (point mutations) or small-scale insertions or deletions (“indels”), the genetic code needs to be deciphered base by base through sequencing. A method that has dominated DNA sequencing for nearly thirty years was presented in 1977 and was named Sanger sequencing after its inventor (Sanger et al., 1977). Basically, the method relies on chain terminating nucleotides (ddNTPs). Sequencing products may be radioactively labeled or, most often nowadays, attached to a fluorescent dye (Smith et al., 1986). The automated application separates the fragmented sequencing products by capillary electrophoresis, after which a laser detector will record the order of the four differentially fluorescently end-labeled ddNTPs. This information is converted to a chromatogram that displays
the nucleotide sequence. Sanger sequencing results in relatively long read-lengths with a high accuracy (Shendure & Ji, 2008).

Next-generation sequencing

During the last decade, the sequencing technology has been revolutionized with the development of methods that have a much higher throughput to a fraction of the cost compared with Sanger sequencing. These new techniques, referred to as next-generation sequencing (NGS), enable massively parallel sequencing of not just one DNA sequence, as by the Sanger method, but millions of different sequences at the same time.

There are several different NGS methods which all consist of three common steps: i) template preparation; ii) sequencing and imaging; and iii) alignment and bioinformatics. The DNA sequenced may represent the entire genome (whole genome sequencing), all exons (exome sequencing), a gene panel (targeted sequencing), or cDNA derived from RNA (transcriptome or RNA sequencing, RNA-seq). In the Illumina platform, applied in Article V, templates are created by fragmentation of DNA and ligation of two different adaptors, needed for subsequent sequencing reactions, to each end of the fragments. The templates are attached to a solid surface and then clonally amplified by bridge PCR that generates clusters, each consisting of numerous templates created from a single DNA strand. The amplification serves to enhance subsequent sequencing signals. One of the two adaptors is cleaved from the surface and the DNA is denatured to make it single-stranded, giving one single sequence in each cluster. Millions of spatially separated clusters enable the next step, i.e., sequencing, to occur in a massively parallel fashion. The sequencing is based on the assembly of DNA strands complementary to the templates, referred to as reads. The reads will be sequenced as they are assembled, so called sequencing by synthesis. The sequencing is performed in a cyclic fashion consisting of base incorporation, imaging, and cleavage. For this purpose, the nucleotides used in the reactions are modified with reversible terminators, which allow only single-base incorporation in each cycle, and one of four fluorescent labels, corresponding to the identity of each nucleotide. After the single-base incorporation, imaging captures the fluorescent signals from all clusters on the surface at the same time. The signal recorded from each cluster is a consensus of all the individual fluorescent signals transmitted from every template constituting that specific cluster. Next, the fluorochrome molecule and terminator are cleaved from the incorporated nucleotide, thereby enabling a new modified nucleotide to be added to the read. Thus, the cycle of incorporation, imaging, and cleavage can be repeated numerous times. Incomplete extension or addition of more than one nucleotide in a given cycle will eventually give rise to signaling dephasing within the cluster, causing base-calling errors and limiting the read length. Hence, the fragments sequenced by NGS experiments are generally shorter than those analyzed by Sanger sequencing. In our experiments, 100 base pairs from both ends of the DNA fragments, paired-end, were
sequenced (Article V). For paired-end sequencing, after the first adaptor has been used for sequencing, a second round of bridge PCR is performed and the second adaptor is used to bind the primer. Each nucleotide will be sequenced several times, usually between 10-1000 times, as the same sequence will be present in multiple clusters. This is referred to as depth of coverage and will determine the strength of the method to identify small clones. The advantage of the NGS technology is its capacity to generate enormous amounts of data; however, advanced bioinformatic pipelines are crucially important in order to extract pathogenetically important findings from the wealth of sequences. The generated reads are aligned to a reference human genome and filtered according to different parameters, such as base quality, alignment score, mapping quality, and PCR duplicates. Next, variant calling analyses are performed, using confidence scores as well as read and variant coverage, to assign SNPs and other genomic variants. NGS can potentially detect the full range of genetic alterations (nucleotide substitutions, indels, CNA, and structural aberrations as well as gene expression levels) depending on the input DNA (Shendure & Ji, 2008; Metzker, 2010; Meyerson et al., 2010; Rizzo & Buck, 2012; Article V).

There are several sources of errors in NGS technology. False positive results can arise as a consequence of errors introduced during template amplification, sequencing, or because of incorrect alignment. False negative results may be due to the fact that some sequences are difficult to capture or map resulting in low coverage. Mutations can also go undetected due to samples being heavily “contaminated” by normal cells (Rizzo & Buck, 2012). Our experience of inconsistent findings obtained by Sanger sequencing and deep sequencing can be demonstrated by the IRS4 mutation (c.670C>A; “p.Pro213Thr; NP_003595.1) detected in Article IV using Sanger sequencing. DNA from this patient was analyzed by deep sequencing in Article V, but in this setting we could not detect this IRS4 mutation. The deep sequencing raw data for the sample in question displayed high IRS4 coverage, approximately 100 reads, with none of the reads displaying the alteration. The case displayed a NOTCH1 mutation with a variant allele frequency of 0.49, indicating a high number of malignant cells in the sequenced sample. We attempted to re-analyze IRS4 with Sanger sequencing but, unfortunately, we were not successful. Hence, we cannot fully explain this discrepancy.

After the samples have been analyzed by NGS, the acquired data need to be interpreted according to the biological context (Lawrence et al., 2013). Which of all the mutations identified are of pathogenetic value? Which genes and mutations will have cancer-initiating/propagating effect (“drivers”) and which are merely passive bystanders (“passengers”)? Matched normal DNA samples as well as information from databases, such as dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), COSMIC (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/), and PolyPhen (http://genetics.bwh.harvard.edu/pph2/), may aid the interpretation regarding the origin (constitutional/acquired) and expected biological impact (driver/passenger) of the variants (Vogelstein et al., 2013). Most previous studies have focused on protein-
altering variants; however, also synonymous mutations, not affecting the protein sequence, have been shown to be selected for in malignant cells, possibly contributing to cancer development (Gartner et al., 2013). It has also been reported that 80% of the genome has biochemical functions; hence, alterations outside the 1% exome may also affect the cellular phenotype (ENCODE Project Consortium, 2012). A very recent report illustrated the potential of intergenic impact by the identification of recurrent duplications in a long-range MYC enhancer, conferring an essential role in NOTCH1-induced T-ALL (Herranz et al., 2014).

**Gene mutations in T-ALL**

Numerous genes are mutated in T-ALL at frequencies equivalent to minor hills in the cancer genetic landscape (Vogelstein et al., 2013). However, the mutation frequency of one gene will reach the peak of Mount Everest – namely, NOTCH1. NOTCH1 is crucial for T-cell fate and differentiation (Radtke et al., 1999). The first indication that NOTCH1 could be of pathogenetic importance in T-ALL came when the translocation t(7;9)(q34;q34) was cloned in 1991 (Ellisen et al., 1991). This translocation, present in <1% of T-ALL cases (Mitelman et al., 2014), results in a truncated and hence constitutively activated form of NOTCH1. However, the central role of this gene was highlighted when activating NOTCH1 mutations were found to occur in more than 50% of T-ALLs (Weng et al., 2004). The oncogenetic potential of activated NOTCH1 has also been demonstrated in mouse models (Pear et al., 1996). NOTCH1 is a transmembrane heterodimeric receptor composed of one extracellular and one transmembrane/intracellular subunit, which interact via the heterodimerization domain (HD). The extracellular unit will bind to ligand molecules (the transmembrane proteins Delta-like 1, 3, and 4; and Jagged 1 and 2) that induce conformational changes and subsequent cleavages of NOTCH1, resulting in the release of the intracellular domain into the cytosol. The NOTCH1 intracellular domain will then translocate into the nucleus where it associates with DNA-binding proteins and cofactors, constituting a complex which will act as a transcriptional activator. NOTCH1 regulates the expression of several genes, mainly those involved in proliferation, metabolism, and cell cycle such as MYC, HES1 (affecting the PI3K-AKT-mTOR signaling pathway), and CCND3 (Paganin & Ferrando, 2011). The phosphorylation of the PEST (proline (P), glutamic acid (E), serine (S), and threonine (T) rich) domain and recruitment of FBXW7 induce NOTCH1 degradation. T-ALL-associated NOTCH1 mutations cluster in the HD, resulting in ligand-independent activation, and in the PEST domain, stabilizing NOTCH1 by impairing degradation. The latter effect can also be accomplished by inactivating mutations in FBXW7, found in 15-30% of T-ALL cases. A proportion, about 20%, of T-ALLs displays dual HD and PEST mutations, or HD and FBXW7 mutations; these co-occurring mutations will work in synergy, optimizing the NOTCH1 signaling (Paganin & Ferrando, 2011; Tosello & Ferrando, 2013). The extensive involvement of aberrant NOTCH1 signaling in T-ALL makes it an attractive target for therapy and, recently, intense research has focused on different ways to inhibit
NOTCH1 activity in T-ALL, something that may result in improved therapy of this disease in the future (Roti & Stegmaier, 2014).

As for NOTCH1, most mutation analyses have focused on one or a few candidate genes, such as FLT3, IL7R, IRS4, JAK1, and NRAS (Bar-Eli et al., 1989; Van Vlierberghe et al., 2005; Flex et al., 2008; Zenatti et al., 2011; Article IV). Although such an approach has been fruitful, it does not provide data on co-operative mutations in the leukemogenesis. More recently, studies applying whole genome, exome, and transcriptome sequencing by NGS have been forthcoming, identifying an average of ten protein-altering mutations per pediatric T-ALL case. These reports have indicated novel genes harboring driver mutations, such as CNOT3, RUNX1, STAT5B, and ribosomal genes. But equally important, the results show that the co-operative effects of mutations affect signaling, transcription, and epigenetics (Zhang et al., 2012; De Keersmaecker et al., 2013; Kalender Atak et al., 2013; Tzoneva et al., 2013; Bandapalli et al., 2014). Although the cost for such analyses is decreasing, they are still quite expensive if a larger number of cases are investigated. Furthermore, to ascertain the relevant mutations, among the thousands of gene changes identified, is a bioinformatic challenge. An alternative is to apply NGS on a gene panel. By targeted deep sequencing it is possible to analyze a list of candidate genes at a greater depth and in a larger cohort than is usually feasible by whole genome NGS, although the genes selected obviously will influence the type of information gained (Fieuw et al., 2012). Targeted sequencing could potentially render data on: i) frequency of known mutations in driver genes; ii) detect new mutations in known driver genes; and iii) implicate new cancer-associated genes in a candidate gene approach (Kalender Atak et al., 2012). In Article V the targeted gene approach was applied on a cohort of pediatric T-ALL patients, revealing mutations affecting signaling transduction (JAK1, JAK3, NRAS, PI3KCA, and PTEN), epigenetic regulators (CREBBP, DNMT3A, EZH2, PHF6, and SETD2), and transcription (BCL11B, FBXW7, NOTCH1, and TCF3).

Genetic aberrations in pediatric T-ALL – take-home message

So, as reviewed above, it is evident that aberrations in numerous genes have been described in T-ALL. Is there any take-home message based on this plethora of alterations? Yes, actually three types of aberration stand out as the genetic backbone in T-ALL, constituting a condensed take-home message: i) TCR translocations: T-ALL characteristic, signature-creating aberrations resulting in deregulated expression of various oncogenes, mainly transcription factors; ii) NOTCH1 mutations: play a critical oncogenic role in T-ALL; iii) CDKN2A deletions: the most common aberration in T-ALL.
Epigenetic alterations

Leukemogenesis is dependent on the co-operative effect of several genetic events targeting the DNA molecule through different mechanisms, as described above. However, it has been known for more than 30 years that epigenetic modifications, *i.e.*, alterations affecting gene expression without altering the DNA sequence, also contribute to tumorigenesis (Feinberg & Vogelstein, 1983). Epigenetic alterations may take place through different mechanisms, such as DNA methylation, histone modifications, and microRNA (Jiang *et al*., 2013).

DNA methylation occurs by DNA methyltransferases (DNMTs) at cytosine (C) bases located 5′ to guanine (G) bases, referred to as CpG dinucleotides. These dinucleotides are often clustered in so called CpG islands, frequently located within gene promoter regions (Burke & Bhatla, 2014). DNMT3A mutations have recently, at a low frequency, been reported in T-ALL (Van Vlierberghe *et al*., 2011; Article V). The cancer genome is globally hypomethylated, while certain CpG islands are hypermethylated. Patterns of methylation have been shown to be disease- and subtype-specific and to discriminate between BCP ALL and T-ALL (Figueroa *et al*., 2013). Promoter methylation often results in gene silencing (Davidsson *et al*., 2009). Hence, identification of hypermethylated promoters can point to tumor suppressor genes. In T-ALL, some of the genes thus identified are ABCG2, CDKN1A, and PAX5 (Van der Meulen *et al*., 2014). Epigenetic data on a number of promoters differentially methylated have been applied in order to propose a CpG island methylator phenotype (CIMP) delineating cases as hypermethylated (CIMP+) or hypomethylated (CIMP-) (Toyota *et al*., 1999; Kraszewska *et al*., 2012c). Indeed, characterizing T-ALLs according to the CIMP phenotype may have prognostic and therapeutic implications (Borssén *et al*., 2013).

The polycomb repressive complex 2 (PRC2) effectuates histone methylation, resulting in transcriptional silencing. The PRC2 consists of EZH2, EED, and SUZ12 and loss-of-function mutations and deletions in the corresponding genes have been reported in T-ALL (Zhang *et al*., 2012; Article V). Similarly, closed chromatin configuration can be achieved by a PHF6 complex and recurrent PHF6 inactivating mutations and deletions occur in T-ALL (Van Vlierberghe *et al*., 2010; Article V). Conversely, histone acetylation is often associated with a more open chromatin conformation, facilitating transcription. Mutations affecting genes involved in histone acetyltransferase, EP300 and CREBBP, are also present in T-ALL (Zhang *et al*., 2012; Article V). It is noteworthy that promoters differentially methylated in T-ALL are enriched for genes with histone modification capacity, such as PRC2 and PHF6 (Kraszewska *et al*., 2012c; Borssén *et al*., 2013).

MicroRNAs are short, single-stranded, non-coding RNA molecules that interfere with mRNA and negatively affect protein translation. MicroRNA can function as both tumor suppressors and oncogenes, depending on their target genes (Mets *et al*., 2014a, b). Since each microRNA may target several different mRNAs due to
incomplete complementarity, it is a challenging and arduous task to predict target genes for individual microRNAs (Esquela-Kerscher & Slack, 2006). A network of microRNAs (miR-20a, miR26a, miR-92, and miR223), displaying overlapping effects on tumor suppressor genes, has been implicated in T-ALL pathogenesis. Genes targeted, and hence deregulated, by these microRNAs have previously been implicated in T-ALL pathogenesis, namely FBXW7, IKZF1, NF1, PHF6, and PTEN (Mavrakis et al., 2011). Interestingly, the expression of microRNAs may be regulated by epigenetic alterations, while at the same time microRNAs can give rise to an aberrant pattern of epigenetic regulators; hence, these factors are intertwined in the control of gene expression (Fabbri & Calin, 2010; Mets et al., 2014).

Gene expression

One way to evaluate how the genotype (DNA) will affect the phenotype (protein) is to characterize gene expression (RNA). However, various subsequent post-transcriptional regulations may affect the accuracy of this approximation (Vogel & Marcotte, 2012). RNA can be analyzed by different methods, such as Northern blot, RT-PCR, RQ-PCR, microarray, and RNA-seq. Northern blot and RT-PCR analyses will mainly show the presence or absence of specific RNAs, while the other methods will add quantitative measurements as well as a potentially global perspective. RT-PCR amplifies cDNA, resulting from RNA reverse transcription, in a cyclic fashion through different temperature stages, enabling denaturation, primer hybridization, and elongation to take place. The efficacy of the PCR is enhanced by the high temperatures at which amplification is accomplished, made possible by heat stable DNA polymerases (Saiki et al., 1988). The end product of RT-PCR will be measured and a positive result signifies that the target RNA was present in the examined sample. RQ-PCR incorporates RT-PCR but is designed to measure also quantitatively the product during PCR progression. The quantification process relies on fluorescent reporter molecules, such as Taqman® probes (Articles I and II). The Taqman® probe is designed with two flanking elements: a fluorescent reporter dye and a quencher. Once the probe has hybridized to the target sequence and the PCR proceeds, the probe will be cleaved. The fragmentation of the probe will separate the quencher from the dye, after which the fluorescent signal can be detected. The intensity of the fluorescence acts as a proxy for the amount of target present in the sample at that specific time. During RQ-PCR there will be an exponential phase, in which the intensity of the fluorescent signal is well beyond background noise; a threshold fluorescence value is established within this phase. The number of PCR cycles necessary to reach the threshold, the Cₜ value, is dependent both on the total amount of RNA present in the initial reaction mixture and on the proportion of target RNA of the total RNA. Housekeeping genes, such as genes encoding rRNA or genes involved in basic metabolism, are utilized as a reference to normalize the Cₜ.
result. Differences in normalized $C_t$ values between samples may be used to calculate variation in gene expression (Bustin, 2000; Jensen, 2012; Articles I and II).

The microarray-based technology was reviewed above (see section “SNP array analysis”). Applications designed to investigate gene expression consist of arrays containing immobilized probes, cDNA or oligonucleotides, representing human genes. Different procedures are available for amplifying and labeling nucleic acids subsequently hybridized to the microarrays. According to the method applied in Article I, RNA is extracted from the investigated sample, amplified, and converted to fluorescently labeled cDNA. In parallel, cDNA from a reference sample is differentially labeled compared with the investigated sample. The reference and the investigated cDNA samples are competitively hybridized to the microarray. The signals are normalized and analyzed, relating signal intensity for both dyes from all probes on the array. The ratio of fluorescence signals between the sample and the control at each array feature conveys the relative difference in gene expression. This difference can be referred to as fold-difference or transformed to a base 2 logarithm of the intensity ratio. This value can then be used for comparison between samples (Sinicropi et al., 2007; Article I).

The technology applied for cDNA sequencing, or RNA-seq, was addressed above (see section “Next-generation sequencing”). The results obtained from RNA-seq overlap with those from microarray analysis in the sense that both methods are able to quantify the global gene expression pattern. However, RNA-seq also provides data on nucleotide substitutions, gene fusions, and alternative splicing. In addition, and in contrast to microarray-based technology, RNA-seq is not limited to investigating the expression of only genes for which there are probes on the array (Ozsolak & Milos, 2011).

The microarray technology has been used for comparison of global gene expression data in samples with known annotations, so called supervised methods. These methods are valuable to construct classifiers, i.e., genes differentially expressed between distinct groups, for prediction of unknown samples to an already defined class. By the use of these methods it has been possible to create reliable classifiers to distinguish T-ALL from BCP ALL (Yeoh et al., 2002). The MRD status in T-ALL can also be predicted already at diagnosis based on gene expression patterns (Andersson et al., 2007). Furthermore, classifiers for known T-ALL-associated oncogenes, such as $TAL1$, $TLX1$, and $TLX3$, have been recognized (Ferrando et al., 2002; Van Vlierberghe et al., 2008b). Some of these gene expression signatures are indicative of leukemic arrest at specific stages of normal thymocyte development; cases with high levels of $TLX1$ or $TAL1$ expression seem to be stalled at the early cortical and late cortical stage, respectively (Ferrando et al., 2002). In unsupervised methods no previous knowledge about the samples is used for analysis of gene expression profiles. Unsupervised analyses have revealed novel oncogenes, such as $HOXA$, SET1/NUP214, $NKX2-1$, and $MEF2C$ in T-ALL (Soulier et al., 2005; Van Vlierberghe et al., 2008b; Homminga et al., 2011). The global property of microarray
analysis is ideal for a discovery phase, with new oncogenes being verified by RQ-PCR (Soulier et al., 2005; Van Vlierbergh et al., 2008b; Homminga et al., 2011). RNA-seq analyses of T-ALL have identified new candidate driver genes, such as \( H3FA \) and \( PTK2B \), classified cases to T-ALL subgroups based on gene expression, and have revealed novel fusion genes encoding activated kinases e.g., \( SSBP2/GER \) and \( TPM3/JAK2 \) (Kalender Atak et al., 2013).

**Tumor evolution**

**Initiating event**

It has been shown that specific genetic aberrations have the potential to give rise to so-called pre-leukemic clones. These clones have been ascribed several characteristics: i) the ability to differentiate into several lineages, indicating a hematopoietic stem cell phenotype; ii) the capacity, after acquisition of additional aberrations, to evolve into leukemia-initiating cells; iii) a propensity to survive chemotherapy, hence acting as a potential reservoir for relapses; and iii) exist in both remission samples as well as in samples from healthy individuals (Shlush et al., 2014). Of all the aberrations and mutations detected in T-ALL, which have the capacity to initiate the leukemogenic process? Oncogenes deregulated by, e.g., TCR translocations, often representing transcription factors or proteins involved in transcription complexes, such as \( TAL1, LMO1/2, TLX1/3, \) and \( HOXA \), have been suggested to possess pre-leukemic potentials (Tremblay & Curtis, 2014). In fact, mouse models have been able to substantiate that \( LMO2 \) expression induces aberrant self-renewal in committed T-cells, hence generating a pre-leukemic clone (McCormack et al., 2010). \( NOTCH1 \) activation has also been implicated as a potential mechanism to generate a pre-leukemic or leukemia-initiating phenotype (Armstrong et al., 2009; Blackburn et al., 2012). Nevertheless, low-level mutation frequencies of \( NOTCH1 \) and T-ALLs being positive for \( NOTCH1 \) at diagnosis but \( NOTCH1 \)-negative at relapse indicate that \( NOTCH1 \) mutations also can be secondary events (Mansour et al., 2007; Clappier et al., 2011; Article V). The cell of origin is also debated. T-ALL-initiating cells, identified through serial mouse transplantation assays, can be traced by the same, original, clonal TCR rearrangement, indicating a probable residue in the committed T-cell progenitor rather than in the hematopoietic stem cell compartment (Armstrong et al., 2009). It has been shown that the majority of TCR translocations will, due to the order of somatic TCR rearrangement during T-cell differentiation, take place in immature, CD1a-negative, DN thymocytes. However, many subgroups of T-ALL have a much later differentiation arrest, at the cortical CD1a-positive stage. Hence, in some cases, the oncogene activation and differentiation arrest may be uncoupled, which would be expected given the necessity for the leukemic clone to accumulate additional aberrations (Le Noir et al., 2012). Conversely, some data indicate that T-ALLs with an immature gene expression profile could evolve from more mature T-cells (Berquam-Vrieze et al., 2011).
Paired diagnostic-relapse samples

Relapsed T-ALL may display one of four different genetic relationships to the major clone at diagnosis: i) identical clones; ii) clonal evolution; iii) evolution from an ancestral clone; and iii) genetically “distinct” leukemia (Mullighan et al., 2008). The most common clonal origin of a relapse appears to be evolution from an ancestral clone (Tosello et al., 2009; Tzoneva et al., 2013; Article V), often present as a minor clone at diagnosis (Mullighan et al., 2008; Clappier et al., 2011). However, even though the relapse clones frequently lose chromosomal markers present at diagnosis and acquire new aberrations, a remarkable genomic stability is noted during the disease progression (Tosello et al., 2009; Article V). Ancestral clones responsible for relapses could in part overlap with the pre-leukemic and leukemia-initiating clones discussed above. It could well be that the relapses considered to be genetically distinct, i.e., with no detected genetic similarities to the diagnostic clone, in fact stem from a common pre-leukemic clone where the initiating event remains unidentified. Relapses evolving from minor subclones could have clinical implications: eradicating the bulk of leukemic cells at diagnosis might not result in cure if therapy-resistant ancestral clones persist.

Tumor heterogeneity in a single leukemia sample

Various kinds of tumor heterogeneity may be considered: i) across different cancer types; ii) between patients with a specific cancer type; and iii) within a single tumor sample (Lawrence et al., 2013; Vogelstein et al., 2013); the latter kind of heterogeneity will be addressed here. As mentioned above, relapses often evolve from a minor clone present at the time of diagnosis. This, thus, indicates a level of clonal heterogeneity at diagnosis. Given that a leukemia originates from a single cell, evolution over time would naturally generate clonal heterogeneity. The clonal composition at diagnosis reflects the different clones proliferate power, and hence selective edge, in response to the biological circumstances at diagnosis. When external circumstances change, e.g., by treatment, a clone different from the major clone at diagnosis could be benefitted and hence evolve to a relapse (Paulsson, 2013; Landau et al., 2014). The possibility to detect genomic heterogeneity has dramatically improved by FISH, SNP array, and, in particular, NGS analyses. For example, in Article V, targeted deep sequencing detected NOTCH1, FBXW7, and PTEN mutations in minor subclones.

Prognostic relevance of T-ALL-associated aberrations

Approximately one in five pediatric T-ALL patients relapses, and for those that do, the prognosis is very dismal; only around 20% survive (Nguyen et al., 2008). The optimal stratification strategy is to predict risk for relapse already at the time of
diagnosis and hence adjust treatment to prevent this from occurring (see section “Treatment, MRD, and prognosis” above). As outlined above, a wealth of data about T-ALL-associated genetic aberrations is now available, elucidating cellular features, such as specific signalling pathways, cell cycle regulators, and transcription factors, important for leukemogenesis. A crucial application of this genetic insight is to seek to improve treatment stratification protocols for T-ALL.

The genes most frequently targeted in T-ALL are \textit{CDKN2A} and \textit{NOTCH1/FBXW7}. Aberrations affecting these genes are detected in >70\% and >50\% of cases, respectively. \textit{CDKN2A} deletions have not conclusively been shown to confer any clinical impact on survival (Ramakers-van Woerden et al., 2001; Krieger et al., 2010; Article V), whereas there are conflicting results with regard to the prognostic significance of \textit{NOTCH1} mutations. Several studies have identified a favorable early therapy response in cases with \textit{NOTCH1} mutations, something that, however, did only translate into improved outcome in some studies (Kox et al., 2010; Zuurbier et al., 2010). This could of course reflect differences in therapy between treatment protocols (Zuurbier et al., 2010). A recent report found a significantly improved overall survival of pediatric T-ALLs with co-occurring \textit{FBXW7} and \textit{NOTCH1} mutations (Jenkinson et al., 2013). However, a positive effect of double \textit{NOTCH1} and \textit{FBXW7} mutations could not be confirmed in Swedish T-ALL patients (Fogelstrand et al., 2014; Article V); however, increased \textit{NOTCH1} activity, as reflected by aberrant \textit{HES1} expression, was associated with improved outcome in one of these cohorts (Fogelstrand et al., 2014). Furthermore, a meta-analysis of 711 pediatric T-ALL patients did not find any correlation between \textit{NOTCH1} mutations and event-free survival (Ma & Wu, 2012).

It has been suggested that specific oncogenes, such as \textit{TAL1}, \textit{LMO1/2}, \textit{TLX1/3}, and \textit{HOXA}, deregulated by TCR translocations, define mutually exclusive subgroups in T-ALL characterized by specific expression patterns (see section “Gene expression” above) (Van Vlierberghe et al., 2008a). Hence, it is possible that the prognosis is mainly associated with these signature-generating genes and not with \textit{CDKN2A} or \textit{NOTCH1/FBXW7}, which are present in all T-ALL subgroups (Jenkinson et al., 2013). Aberrant expression of \textit{TAL1} and \textit{TLX1} has been suggested to confer a more favorable prognosis, while \textit{TLX3} has been associated with a dismal outcome in some, but not all, studies (Van Vlierberghe & Ferrando, 2012). Finally, we found that rare TCR translocations correlated with an inferior prognosis (Article III); however, this has, as of yet, not been confirmed in a separate study. In conclusion, no genetic aberration in T-ALL has so far been clearly shown to be an independent prognostic marker.
Synopsis of the articles included in the thesis

**Articles I and II** focus on molecular characterization of rare translocations involving TCR loci. These types of aberration are characteristic for T-ALL and have previously proved pivotal in the identification of genes implicated in T-cell oncogenesis. The first investigated translocation, t(12;14)(p13;q11), was shown to result in overexpression of \( CCND2 \). The \( t(12;14) \) is the first neoplasia-associated translocation shown to result in overexpression of \( CCND2 \) and the first example of a targeted deregulation of a member of a cyclin-encoding gene family in T-ALL. Cyclin D proteins are crucial to the cell cycle machinery and hence potential oncogenes. The second translocation cloned, \( t(X;7)(q22;q34) \), had not previously been reported in a neoplastic disorder. Breakpoint analysis revealed \( IRS4 \) as a novel translocation partner to a TCR locus, resulting in deregulated \( IRS4 \) expression, both at the gene and protein level. \( IRS4 \) plays an important role in several intracellular signalling cascades, including PI3K-AKT, known to be activated in T-ALL. In a subsequent work, I could show that \( IRS4 \) is also targeted by alternative mechanisms in T-ALL, apart from TCR translocations, namely by mutations (**Article IV**).

In **Article III**, clinical characteristics and cytogenetic aberrations were ascertained and reviewed in a large, population-based Nordic series of 285 pediatric T-ALLs. The clinical characteristics of our Nordic cohort agreed well with previous larger series: a median age of 9 years, male predominance (male/female ratio 3.1), median WBC count of \( 66.5 \times 10^9/l \), and a high incidence of mediastinal mass and CNS involvement. Survival analyses revealed a correlation between rare TCR translocations and inferior outcome, an association that still awaits confirmation in a separate study.

Finally, I used several different techniques – such as FISH, SNP array, and deep sequencing of 75 selected candidate genes – to characterize co-operative genetic aberrations in a consecutive series of pediatric T-ALL (**Article V**). One common change identified by SNP array was sUPID. This aberration was seen in 44% of the investigated cases; most were sUPID9p that always were associated with homozygous \( CDKN2A \) deletions, with a heterozygous deletion occurring prior to the sUPID9p in all instances. Among the 75 genes investigated by deep sequencing, 14 were mutated in 28 cases. The genes targeted are involved in signalling transduction, epigenetic regulation, and transcription. In some cases, \( NOTCH1 \) mutations were seen in minor
subclones and lost at relapse, showing that such mutations also can be secondary events.

In summary, through different approaches and by various methods, the articles included in this thesis have deciphered genetic aberrations in pediatric T-ALL, thus contributing to a better understanding of leukemogenesis.
Future Perspectives

The mountains representing genes altered frequently in T-ALL have been explored, and it is unlikely that any major peak has gone undiscovered. Numerous hills, i.e., genes targeted infrequently, are known, but some still await exploration. However, the identification of genes rarely involved in T-ALL will probably not dramatically change the understanding of the cancer genetic landscape. So, which genetic roads are less travelled by and may hence make all the difference in the future?

There is currently a massive tide of sequence data sweeping across the genetic landscape. The majority of NGS studies has focused on protein altering aberrations. When this approach has reached its potential, it may be fruitful to learn more about alterations affecting the genetic sequence but not the amino acid code, so called synonymous or silent mutations. Even though these variants are not protein-altering, they may affect protein confirmation and expression, hence potentially contributing to oncogenesis. Whole genome NGS generates extensive data also on the 99% of the genome that is non-protein coding. It is now well recognized that these extensive DNA stretches are not, as it was once considered, “junk DNA”; instead the majority of the genome participates in biochemical RNA- and/or chromatin-associated events. Thus, also genetic alterations in non-coding regions could affect cellular functions and hence be of interest to address in cancer genomes.

What impact do DNA alterations have on the RNA level? Transcriptome analyses in T-ALL are so far limited in number, but will probably add valuable information on the phenotype of the leukemic cells in the future. In addition, are all the hills seen in the global genetic analyses part of a greater picture? Is it possible to transform the seemingly high level of mutation heterogeneity to a limited number of cellular pathways in the majority of T-ALL cases? If so, are there candidates in these pathways that are suitable to target for therapy? Already, a few crucial genes and signaling pathways in T-ALL are known and clinical trials with NOTCH1 inhibitors are promising, although they have not proved to be the sole salvation. Hopefully, with increasing knowledge about aberrant signaling pathways, multiple specific genes may be targeted which could render synergistic effects against T-ALL. Alterations in genes involved in epigenetics have just recently been implicated in T-ALL. Still, the epigenetic patterns in T-ALL have been addressed in relatively few studies and to explore further this avenue might lead to new insights in T-ALL.
With new technical solutions constantly pushing the limit for what can be achieved and an ever growing knowledge to build on, there is good reason to believe that future efforts will dispel the haze that linger over the cancer genetic landscape in T-ALL.

Varför drabbas vissa barn av leukemi? Vi vet inte det säkert. Troligen är det så att en del barn har en medfödd genetisk sårbarhet för denna sjukdom och i kombination med olika omgivningsfaktorer, såsom infektioner, kan leukemi uppstå. Det vi vet är att all cancer, också leukemi, orsakas av genetiska förändringar i cellen. Celler ska dela sig, mognas till specialiserade celler (differentiera) och så småningom dö; dessa cellulära processer är strikt reglerade. Genetiska förändringar kan sätta cellens regelsystem ur funktion, något som kan leda till snabb celldelning, utebliven differentiering och förlängt liv av cellen; d.v.s. karakteristiska egenskaper för cancerceller. I de flesta fall behöver ett flertal specifika genetiska avvikelser ansamlas i en och samma cell för att den ska förändras till en cancercell.

Genetiska avvikelser kan påverka prognosen, d.v.s. sjukdomens förlopp, för barn med ALL. Möjligheten att kombinera flera typer av cytostatika och ge olika intensiv behandling beroende på vilka genetiska förändringar som ses vid diagnos har bidragit till att förbättra prognosen för barn med leukemi; på 1960-talet överlevde endast 5% av barnen, idag botas drygt 90%. Som framgår ovan har dock patienter med T-ALL en sämre överlevnad. Till viss del kan detta bero på att vi fortfarande inte säkert vet om det finns specifika genetiska förändringar som påverkar prognosen vid T-ALL. Detta innebär att det inte finns så stora möjligheter idag att justera behandlingen för barn med T-ALL.

Mitt avhandlingsarbete har fokuserat på att beskriva och analysera genetiska avvikelser hos barn och ungdomar med T-ALL samt att undersöka om några genetiska förändringar kan användas för att bedöma prognosen.

T-ALL är en ovanlig sjukdom, men genom ett samarbete med Nordisk förening för pediatrisk hematologi och onkologi (NOPHO) har det varit möjligt att analysera data
från 285 barn och ungdomar som insjuknat i T-ALL mellan 1992 och 2006 i de Nordiska länderna. Fynden har dels lett till att vi kunde bekräfta att tidigare internationella resultat även gäller barn i Norden: T-ALL drabbar pojkar tre gånger så ofta som flickor, medianåldern vid insjuknandet är 9 år, patienterna har ofta ett högt antal vita blodkroppar i blodcirkulationen, många gånger återfinns en stor tumörmassa i mediastinum (utrymmet bakom bröstbenet) och leukemiceller har även ibland spridit sig till centrala nervsystemet. Studien har även givit ny kunskap om genetiska avvikselser och prognos. Hos hälften av patienterna ses genetiska förändringar i de sjuka cellerna vid en kromosomanaly. En återkommande avvikelse är en s.k. translokation. En translokation innebär att genetiskt material har bytt plats mellan två kromosomer (Figur 6). Vilket genetiskt material, d.v.s. vilka gener, som ingår i leukemiasättade translokationer är inte slumpartat. Vid T-ALL är ofta gener som kodar för T-cellsreceptorer (TCR) involverade och dessa TCR-translokationer har betydelse för uppkomsten av T-ALL. I min studie fann vi att patienter med ovanliga TCR-translokationer tenderade att ha en sämre prognos (Artikel III).


Då en 14-årig flicka och en 1-årig pojke fick diagnos T-ALL påvisade kromosomanalyserna en translokation mellan den korta armen, p, på kromosom 12, och den långa armen, q, på kromosom 14; t(12;14)(p13;q11) (Figur 6, Artikel I). Molekylärgenetiska analyser identifierade brottspunkter i TCR-genen samt i närheten av genen för cyklin D2 (CCND2). Analyser som undersöker geners uttryck kunde påvisa ett högt uttryck av CCND2 i båda fallen med t(12;14) jämfört med T-ALL-fall som inte hade denna translokation. Detta är den första translokationen som har visats påverka uttrycket av cyklin D2. Cyklin D-proteiner medverkar till att cellen växer och delar sig. En ökad mängd av dessa proteiner har tidigare visats vara involverade i en rad olika cancerformer. Det pågår nu försök att behandla T-ALL genom att specifikt blockera cyklin D-proteiner.
Figur 6. Vad är en translokation?
Om två kromosomer klipps av och lagas med varandra bildas nya kromosomer, s.k. translokationer. Figuren illustrerar den TCR-translokation som beskrivs i Artikel I. Kromosomerna 14 och 12 klipps av (brottspunkter) i banden q11 respektive p13. En TCR-gen finns i brotts punkten på kromosom 14. Denna gen har en stark positiv inverkan på sin nära omgivning, symboliserat av en sol. CCND2, belägen nära brotts punkten på kromosom 12, är en gen som gör att cellen kan växa och dela sig, symboliserat av ett träd. Då TCR-translokationen t(12;14)(p13;q11) bildas hamnar TCR-genen och CCND2 i närheten av varandra. Drivkraften, solen, som TCR-genen bär med sig kommer då att ha en positiv inverkan på, d.v.s. ge ett ökat uttryck av, CCND2. Det ökade uttrycket innebär att mer CCND2 bildas vilket leder till att cellen växer och delar sig, illustrerat av skogen.

Den andra ovanliga TCR-translokationen som ingår i mitt avhandlingsarbet sågs vid diagnos hos en 12-årig pojke. Material mellan kromosomerna X och 7 hade bytt plats, t(X;7)(q22;q34), en förändring som inte tidigare hade rapporterats i T-ALL eller i någon annan cancerform. Brottspunkten i kromosom 7 visades vara i, eller i närheten av, en TCR-gen och X-brottspunkten var nära genen IRS4 (Figur 4, Artikel II). Analyser visade att uttrycket av IRS4 var förhöjt på både gen- och proteinnivå i fallet med t(X;7) jämfört med andra T-ALL-fall utan denna translokation. Detta var första gången IRS4 visats vara en partner i en TCR-translokation och överuttryckt i T-ALL.
Jag har i en kompletterande studie visat att IRS4 även kan vara förändrad genom mutationer, d.v.s. skrivfel i DNA-strängen, i T-ALL (Artikel IV). IRS4 aktiveras i cellen av olika signalmolekyler och kan därefter aktivera ett flertal proteiner, såsom PI3K, vilka medverkar till ökad tillväxt och celldelning. Detta är egenskaper som selekteras för i cancerutvecklingen, något som talar för att IRS4 kan vara viktig för uppkomst av T-ALL.


Sammanfattningsvis har jag i mitt avhandlingsarbete genom en rad olika studier undersökt vilka genetiska förändringar som finns i leukemiceller hos barn med T-ALL. Mitt och många andra forskares arbete har lett till att sjukdomsassocierade förändringar i gener i T-ALL nu är tämligen väl kartlagda. Det som framöver behöver belysas är genetiska förändringar som finns i den stora del av vår arvsmassa som inte är gener och som därmed inte ger upphov till protein men som trots det skulle kunna påverka leukemiutvecklingen. Ytterligare undersökningar behöver också utföras av det s.k. epigenetiska mönstret i leukemiceller. Epigenetik innebär att genuttryck kan regleras utan att DNA-strängen förändras. Slutligen, även om vi idag har kunskap om avvikelser i gener vet vi inte så mycket om i vilken utsträckning dessa förändringar verkliga överställs till proteiner. Att fortsätta studera genuttryck och proteiner kan ge ledträdar om vilka byggstenar som faktiskt finns i leukemiceller. Att finna genetiska avvikelser med prognostisk innebörd i T-ALL har visat sig vara svårt. Dock har den ökade kunskapen om genetiska avvikelser vid T-ALL lett till att man har identifierat några viktiga gener och signalvägar, t.ex. NOTCH1 och gener som påverkar celldelningen såsom CDKN2A och cyklin D samt signalvägar involverande PI3K, som nästan alltid används av leukemicellen. Försök pågår nu att med olika läkemedel blockera effekten av förändringar i dessa gener, något som förhoppningsvis kan leda till effektivare behandling för patienter med T-ALL.
Acknowledgments

One of the things I enjoy most in life is to travel. In a way, the work with this thesis has been like a journey. I received my scientific passport in May 2007 when I was accepted as a PhD student. Since then I have learned a new language, in which words like illegitimate recombination and targeted re-sequencing are common. I have used many kinds of techniques, such as FISH, SNP array, Western blot, and NGS as means of transportation to reach genetic destinations. Taking the FISH trip was like sailing at night looking at the stars, Western blot was a bumpy ride, and NGS took me with the speed of a Concorde flight to completely new surroundings. Sometimes the destination was not what I expected or was already too crowded, but on a few occasions the journey took me to exciting places no one had ever seen before. I would then write letters to those left behind describing my discoveries, in the language I tried to master. But as always with travels, even though the sights are thrilling, the memories that linger are of the people you meet along the way. During my PhD expedition I have met many fantastic people who helped me when my luggage was heavy, joined me for a chat when the sights confused me, pointed me into the right direction when I was lost, and listened to my stories when I returned home. I want to mention a few who have been extra important to me on my road towards this thesis:

**Bertil Johansson**, my supervisor. I could not have wished for a better guide for this scientific expedition! You organized the itinerary, explained the route to me, but allowed me to test the path on my own. Sometimes I missed a connecting flight (I had a baby) or lost my passport (much work at the clinic), but you always waited patiently for me to return. When my destination turned out to be mentioned in the guidebook already, you encouraged me to keep looking for the unknown. And when I actually reached land unheard of, you shared my enthusiasm for the new discoveries. You were fantastic in phrasing the scientific letters, always finding the right words to elucidate the salient findings of our endeavors. You have been extremely generous with your time, giving me the opportunity to discuss with you reports from all parts of the cancer genetic landscape, teaching me how to learn from them. This journey would not have been the same without you. Thank you.

**Kajsa Paulsson** and **Thoas Fioretos**, my co-supervisors. I appreciate your interest in and support of my projects. Kajsa, I especially value your help with the SNP maps, deciphering the hills and valleys hidden there.
Felix Mitelman, founder of the Department of Clinical Genetics. Felix, you have more stamps in your scientific passport than most of us can dream of. Your amount of frequent flyer points entitles you to sit in the executive lounge and sip Champagne. But instead, you join me and my colleagues daily in the general waiting area, patienthotellet, and I greatly enjoy all our discussions: from science, to literature, to how to grow the perfect lawn.

Catarina, Fredrik, Hans, Jacob, Kajsa, Maria, Nina, Samuel, and Ulf, clinical colleagues. You have generously and with great knowledge guided me on my parallel but intertwined journey, in the field of clinical genetics. But maybe more important in this context, you made me forget about my travelling nerves. Over coffee we discuss small and big things, you make me laugh, we dance together at conference parties, and we have interesting lunch talks. I feel privileged to share my working days with you.

Linda and Setareh, PhD colleagues. You have been such generous and fun travel companions. The trip to San Francisco was amazing. Linda, when I got all confused in the sequencing landscape you always turned up to show me the way ahead. I also want to thank Eleanor, Kristina, and Rebeqa, in my research group, for encouragement along the way. Principle investigators, postdocs, PhD students, technicians, and other personnel at the Department of Clinical Genetics, you constitute a fantastic scientific homeland and it has been very educational to hear your reports from various foreign destinations during the Friday seminars. Anette, thank you for keeping track of all the logistics that comes with travelling.

Andrea, Bodil, Carin, and Margareth, laboratory engineer and technicians. It is an art to make the techniques run smoothly to the places you want to go. You master this art, thank you for all your assistance.

Anna, Emma, Nisse, Petra, and Tord, colleagues and hospital geneticists. Thank you for all the time you have taken to explain the wonders of chromosome banding, FISH, SNP array, and sequence analyses to me. Your expertise has been an important part of my guidebook to this adventure.

Everyone at the Clinic. In your competent care I have gradually grown into a clinical geneticist. Thank you for helping me along the way.

ST-ALF and Barncancerfonden, thank you for the financial contributions that made the new discoveries possible.

Mamma och Pappa. Min färd mot avhandlingen har tagit lång tid men utan all er hjälp hade den tagit ännu mycket längre tid. Tack för alla gånger ni hämtat och passat barnen och för att jag vet att de alltid har det så fint hos er. Det är också med er jag
gjort mina första resor, ofta på upptäcktsfärder i Europa. Er entusiasm för resande bär jag nu med mig.


**Cissi**, min bästa vän. Vi har rest tillsammans, till geografiska och litterära platser. Jag uppskattar alltid ditt sällskap.


**Anton och Emma**, mina fina barn. Den nya resan är tillsammans med er. Några ord på färden:

```
Alla de försiktiga med långa håvar
träffar havets jättekrar.  
Vänner, vad söker ni på stranden?  
kunskap kan aldrig fångas,  
kan aldrig ägas.

Men om du rak som en droppe  
faller i havet att upplösas,  
färdig för all förvandling –  
då skall du vakna med pärlmorhud  
och gröna ögon  
på änger där havets hästar betar  
och vara kunskap.
```

Karin Boye
References


Bennett JH. (1845) Case of hypertrophy of the spleen and liver, in which death took place from suppuration of the blood. *Edingburgh Medical and Surgical Journal* 64: 413-423.


82


